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Abstract
Seasonal influenza outbreaks are associated with morbidity and mortality in the United
States. Though children are the most susceptible to influenza infection and are most
likely to transmit the illness to others, many children are not vaccinated. The purpose of
this study was to examine the relationship between seasonal influenza vaccination
Advisory Committee on Immunization Practices (ACIP) recommendations, demographic
characteristics, socioeconomic factors, and vaccine type among children over 3
consecutive flu seasons. This quantitative cross-sectional study was guided by the social
ecology of health model. Secondary data from 3 consecutive flu seasons (2014-2015,
2015-2016, and 2016-2017) provided by the National Health Interview Survey was used
for this study. Binary logistic regression and chi-square were used to analyze the data. A
relationship between socioeconomic status, demographics (age, race, and family income)
and vaccine type (live-attenuated influenza vaccine [LAIV]/inactivated influenza
vaccine) was established among U.S. children; those who received LAIV were most
likely to be White elementary school age children with a higher family income.
Demographic and socioeconomic status was not considered influential in LAIV uptake
for race, health insurance status, or family income. ACIP recommendations by age and
year had the greatest impact on flu vaccine choice for this sample population. The results
of this study can lead to social change by providing information for policy that can
increase vaccine uptake, which can result in lower health cost and reduced illness and
death rates associated with the flu, especially for those most at risk.
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Section 1: Foundation of the Study and Literature Review
Introduction
In the United States, seasonal influenza outbreaks are associated with morbidity
and mortality (Hull & Ambrose, 2011; Weycker et al., 2005; Wilson, Sanchez,
Blackwell, Weinstein, & El Amin, 2013). The most effective method for preventing
influenza and its complications is annual fall influenza vaccinations (Weycker et al.,
2005). Although annual influenza attack rates can be as high as 42% among school-age
children (Carpenter et al., 2007), and children are most likely to transmit the illness to
others, many children do not receive influenza vaccination. Increasing the number of
children immunized against the flu also increases herd immunity by the indirect
protection of household and community members (Lind et al., 2014).
The live-attenuated influenza vaccine (LAIV) was developed to address issues
associated with production and dissemination of the influenza vaccine for potential
influenza pandemics and mass vaccination (Penttinen & Friede, 2016). Production of the
inactivated influenza vaccine (IIV) takes time, and administering the vaccine requires
basic safety and infection control measures due to its injectable nature. The LAIV option
was ideal for mass vaccination of children, especially in a pandemic situation, due to its
efficacy, production yield, availability for unanticipated serotypes, and user-friendly
application (Penttinen & Friede, 2016). Roughly 30% of children vaccinated for the flu
each year receive the LAIV, when available, whereas the other 70% receive the shot (IIV;
Kahn, Santibanez, Zhai, & Singleton, 2015).
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Annual surveillance and vaccine effectiveness research is conducted to improve
influenza vaccines, anticipate seasonal virus strains, and track the circulation of influenza
in the community (Kelly et al., 2009). Initial studies with comparisons of LAIV and IIV
efficacy in young children indicated that LAIV is more effective than IIV for preventing
the flu in children 2 to 8 years of age (Belshe et al., 2007). But subsequent studies have
had conflicting results with the diminished effectiveness of the LAIV across all
circulating influenza virus as opposed to IIV (Caspard et al., 2016; Eick-Cost et al., 2012;
Flannery & Chung, 2016).
The topic of this study is the relationship between the Advisory Committee on
Immunization Practices (ACIP) flu vaccine recommendations, socioeconomic factors,
demographic characteristics, and vaccine type among U.S. children. In addition to the
reported inconsistencies in flu vaccine efficacy, annual influenza vaccine
recommendations have varied in children 2 to 8 years of age. In 2016, data from four
observational studies evaluating influenza vaccine effectiveness in the pediatric
population during the 2015-2016 influenza season was presented to the ACIP (Flannery
& Chung, 2016). The two studies conducted in the United States showed decreased
effectiveness of LAIV compared to IIV (Grohskopf et al., 2016). However, studies in the
United Kingdom and Finland showed the statistically significant efficacy of LAIV
against all influenza strains ranging from 46% to 58%. These studies show LAIV and IIV
effectiveness comparable to vaccine effectiveness in observational studies in prior
seasons (Rhorer et al., 2009). Inconsistencies in vaccine recommendations impact
vaccine uptake by diminishing the patients’ perceived benefits of following these vaccine
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recommendations (Mueller, Hill, Fontanesi, & Kopald, 2007). For example, studies have
shown that parents who delayed and refused vaccine doses were more likely to have
vaccine safety concerns and perceive fewer benefits associated with these vaccines (Blyth
et al., 2014; Cheney & John, 2013; Smith et al., 2011).
This study is significant because the relationship between influenza vaccination
recommendation by the ACIP and vaccine uptake among children is not known, leaving a
gap in the literature. The potential positive social change and implications of this study
include analysis of factors associated that could impact vaccine choice and help to
improve vaccine recommendations and policies. The major sections of this chapter
include the problem statement, study purpose, research question, theoretical foundation,
nature of the study, literature review, and significance. The chapter will also include
discussion of the assumptions, study scope, limitations, and significance of the study.
Problem Statement
The ACIP is a group of public health and medical and medical experts who
develop recommendations on vaccine use among the civilian population of the United
States for all children 6 months to 18 years of age before the annual influenza season
(Hamborsky, Kroger, & Wolfe, 2015). There are two types of inﬂuenza vaccines
available for children in the United States. These vaccines are either IIV (contains
inactivated form of the virus) administered by shot or LAIV (contains a weakened form
of the virus) a nasal mist (Flannery & Chung, 2016; Hamborsky, Kroger, & Wolfe, 2015;
Kahn et al., 2015). The LAIV has increased in popularity since its introduction in 2003.
For flu seasons 2011-2012, 2012-2013, and 2013-2014, over 30% of vaccinated children
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received the LAIV (Kahn et al., 2015). In 2013 the ACIP recommended preference for
LAIV, when available, for children 2 to 8 due to its efficacy compared to the IIV (Centers
for Disease Control and Prevention [CDC], 2014). But the subsequent annual influenza
efficacy research has indicated a reduction in LAIV efficacy against A/H1N1 in the
United States (determined by a few test-negative, small sample size studies), resulting in
ACIP no longer recommending the LAIV for any age group for the 2016-2017 flu
season, though the LAIV vaccine will still be manufactured and available for use
(Grohskopf et al., 2016).
Discontinued recommendation of the LAIV by the ACIP because of reduced
vaccine efficacy can reduce vaccination rates among children. According to Healthy
People 2020, the ideal influenza vaccination rate of children is at least 70%, though each
year actual vaccination rates fall short of the recommended threshold, ranging from 31.1
to 59.3% of children ages 6 months to 17 years of age since 2007 (Peng-jun Lu et al.,
2013; Rose et al., 2014). Because the LAIV vaccine was recommended from the 20032004 through the 2015-2016 flu seasons, little is known about the relationship between
ACIP recommendations to discontinue LAIV recommendations and the impact of
influenza vaccine uptake in the pediatric population.
Purpose of the Study
This study was conducted to evaluate the association between seasonal influenza
vaccination ACIP recommendations, socioeconomic factors, demographic characteristics,
and vaccine type among children over three consecutive flu seasons. LAIV was the
recommended choice for children 2-8 during the 2014-2015 flu season, both LAIV and
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IIV were equally recommended for the 2015-2016 flu season, and the LAIV
recommendation was discontinued for the 2016-2017 season due to studies showing
limited efficacy against A/H1N1 (Flannery & Chung, 2016). In addition, multiple
socioeconomic and demographic factors can influence vaccine choice including age, race,
family income, and health insurance status. The dependent variable for this study was
influenza vaccine type (LAIV and IIV) among U.S. children. The independent variables
were age, race, family income, health insurance status, and ACIP influenza vaccine
recommendation by flu season (2014-2015, 2015-2016, and 2016-2017).
Research Questions and Hypotheses
Research Question 1: What is the relationship between age, race, family income,
health insurance status, and vaccine type (LAIV/IIV) among U.S. children for flu season
2014-2015?
H01: There is no relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/IIV) among U.S. children for flu season 2014-2015.
Ha1: There is a relationship between age, race, family income, health insurance
status, vaccine type (LAIV/IIV) among U.S. children for flu season 2014-2015.
Research Question 2: What is the relationship between age, race, family income,
health insurance status, and vaccine type (LAIV/IIV) among U.S. children for flu season
2015-2016?
H02: There is no relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/IIV) among U.S. children for flu season 2015-2016.
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Ha2: There is a relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/IIV) among U.S. children for flu season 2015-2016.
Research Question 3: What is the relationship between age, race, family income,
health insurance status, and vaccine type (LAIV/IIV) among U.S. children for flu season
2016-2017?
H03: There is no relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/IIV) among U.S. children for flu season 2016-2017.
Ha3: There is a relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/IIV) among U.S. children for flu season 2016-2017.
Research Question 4: What was the relationship between influenza vaccine type
(LAIV/IIV) of U.S. children and ACIP recommendations indicated by flu seasons 20142015, 2015-2016, and 2016-2017?
H04: There is no relationship between influenza vaccine type (LAIV/IIV) of U.S.
children and ACIP recommendations indicated by flu seasons 2014-2015 (LAIV
preferred), 2015-2016 (LAIV & IIV) and 2016-2017 (IIV preferred).
Ha4: There is a relationship between influenza vaccine type (LAIV/IIV) of U.S.
children and ACIP recommendations indicated by flu seasons 2014-2015, 2015-2016,
and 2016-2017.
Theoretical Foundation for the Study
Social Ecological Model
The use of ACIP recommendations, demographic characteristics, and
socioeconomic status to evaluate influenza vaccine choice is guided by the social
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ecological model. Although ACIP recommendations are not mandates, they may
influence the availability of vaccines to consumers and their uptake in society. Once
individuals have determined the need for the vaccine on a personal level, they look to
public opinion and policy for guidance.
The social ecological model identifies multiple factors that influence health
behavior including the individual, interpersonal, institutional, community, and policy
levels. The intrapersonal level is where health decisions are made based on personal
beliefs and knowledge at the individual level. The interpersonal level is focused on social
norms, influence in the community, and collective beliefs within a close social network
(Kumar et al., 2012). This level consists of peers, general practitioners, family, and
friends. The institutional level represents the health care system, medical institutions, and
local health care practitioners. At the community level are media, health disparities, and
social norms. For example, vaccine uptake increases as more people in the same
community get vaccinated (Kumar et al., 2012). At the policy level is regulation,
oversight, and governing recommendations.
Variables at each level in the social ecological model are predictors of vaccine
uptake (Kumar et al., 2012). In this case, patients have already made a choice to take the
vaccine, so uptake was met at the intrapersonal level. For this study, the community and
institutional levels of the social ecological model are represented by demographic and
socioeconomic status. The policy level of the social ecological model is represented by
ACIP recommendations. Although all levels affect vaccine uptake and choice, policies,
socioeconomic and demographic factors can directly influence the other levels by altering
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and influencing the access and desire of flu vaccinations. This is achieved by making
certain vaccines unavailable, altering access, reducing their perceived effectiveness,
limiting affordability, or indicating a belief of risk associated with their use. For example,
the ACIP recommendation to discontinue use of LAIV for the 2016-2017 flu season can
negatively influence influenza vaccine uptake. If the underlying cause of LAIV’s reduced
efficacy is not defined and addressed due to conflicting policy and inconsistent
recommendations by governing bodies, local health departments, and family
practitioners, the public is left with limited or conflicting information to help guide
vaccine choice.
Nature of the Study
This study was a quantitative cross-sectional study with secondary surveillance
data provided by the CDC. The nature of this study is focused on ACIP recommendations
and socioeconomic status and demographic characteristics regarding how they translate
to vaccine choice among children residing in the United States. Secondary publicly
available data were used to evaluate vaccine uptake by type among children over three
recent flu seasons (2014-2015, 2015-2016, and 2016-2017) with different children
sampled each year.
The key study variables include vaccine uptake of LAIV or IIV among U.S.
children over three consecutive flu seasons with differing ACIP recommendations in
addition to demographic and socioeconomic status defined as age, race, family income,
and health insurance. The population for this study includes children (0 to 17 years of
age) over three consecutive flu seasons (2014-2015, 2015-2016, and 2016-2017). The
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sample population for influenza vaccinations is provided by the National Health
Interview Survey (NHIS). The NHIS is a cross-sectional household interview survey
conducted continuously throughout each year. Data are collected by the U.S. Census
Bureau employees through a personal household interview consisting of four major
components: household, family, sample adult, and sample child.
Literature Search Strategy
A search of relevant literature was done in the following databases:
ScienceDirect, Google Scholar, Walden Library, and NIH. Search terms included liveattenuated influenza vaccine, LAIV, vaccine effectiveness, vaccine efficacy, LAIV, ACIP
flu, health belief model vaccinations, child influenza, and influenza vaccine. Peerreviewed articles and CDC reports were chosen to provide the most recent information.
Articles focused on side effects or risk associated with the flu vaccine were excluded
because they did not relate to the study topic. This initial literature search identified
around 87 documents for further review and analysis.
Literature Review
Influenza is primarily transmitted from person to person via airborne-infected
droplets that are disseminated when an infected person sneezes or coughs. These infected
droplets can be transferred to susceptible persons within 3 feet of the infected individual.
Transmission can also occur through direct or indirect contact with contaminated surfaces
(Hamborsky et al., 2015). Humans are currently the only reservoir of influenza types B
and C, although influenza A viruses infect both humans and animals (Hamborsky et al.,
2015). Influenza activity generally peaks from December to March in temperate climates
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and occurs throughout the year in tropical regions (Deyle, Maher, Hernandez, Basu, &
Sugihara, 2016). Adults can transmit influenza for 6 days from 1 day before symptoms
appear to the first 5 days of the illness, and children can spread influenza for 10 or more
days (Hamborsky et al., 2015). Once infected, the influenza virus penetrates respiratory
epithelial cells where replication occurs resulting in the destruction of the host cell
(Hamborsky et al., 2015)
The flu is rapidly transmitted in large populations with close contact, especially in
the fall and winter months during the traditional academic school year. Seasonal
influenza is estimated to impact 10 to 20% of the United States population annually (Hull
& Ambrose, 2011). School-age children have the highest influenza transmission and
infection rate, ranging from a 10 to 40% attack rate yearly (Wilson et al., 2013).
Additionally, according to the CDC (2016), pediatric mortality is highest between 5 and
11 years of age, especially when combined with a secondary bacterial infection. Further,
annual influenza attack rates among school-age children, who transmit the infection to
others, can be as high as 42% (Carpenter et al., 2007). However, annual fall influenza
vaccinations are the most effective method for preventing influenza and its complications
(Weycker et al., 2005). The vaccination of children has been shown to reduce the impact
of influenza on the communities where they reside, which is important for at-risk
populations such as those 65 years of age and older (Wilson et al., 2013). Thus, the
World Health Organization recommends a seasonal flu vaccination consisting of a 75%
coverage rate for high-risk populations (Longini & Halloran, 2005).
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Influenza Vaccine and Advisory Committee on Immunization Practices
Recommendations
There are two types of inﬂuenza vaccine available for children in the United
States. These vaccines are either IIV (administered by shot) or LAIV (a nasal mist) and
contain influenza type A(H1N1), type A(H3N2), and type B (Caspard et al., 2016;
Hamborsky et al., 2015). The LAIV has increased in popularity since its introduction in
2003. For flu seasons 2011-2012, 2012-2013, and 2013-2014 over 30% of vaccinated
children received the LAIV (Kahn et al., 2015). In 2013 the ACIP recommended
preference for LAIV, when available, for children 2 through 8 due to its vaccine efficacy
compared to the IIV (CDC, 2014). Subsequent annual influenza efficacy research has
indicated a reduction in LAIV potency against A/H1N1 in the United States, resulting in
ACIP no longer recommending the LAIV for any age group for the 2016-2017 flu season
(Robinson, 2016).
The ACIP recommends influenza vaccination for all children 6 months to 18
years of age before the annual influenza season. The CDC identified the average flu
season beginning in October each year and extending through March of the following
year (Peng-jun Lu et al., 2013). Due to the inconsistent nature of the annual flu season
and vaccine uptake, data will be aggregated by month to include 6 months of each year
for a total of 12 months. Therefore, the 2014-2015 season was from July 1, 2014, to June
31, 2015, flu season 2015-2016 from July 1, 2015, to June 31, 2016, and season 20162017 include July 1, 2016, to June 31, 2017.
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Inactivated Influenza Vaccine (IIV)
Influenza vaccination only provides temporary immunity due to antigenic drift
which contributes to seasonal outbreaks of the flu virus. For the IIV influenza conferred
immunity is less than a year and depends on the individual and circulating flu strains
(Hamborsky et al., 2015). Studies show influenza vaccines are effective in protecting
about 60 % of healthy people under age 65 years when seasonal strains are closely
matched (Tricco et al., 2013). The Influenza vaccine is less effective in populations over
65 years old in preventing illness but may reduce the duration and severity of the illness
resulting in reduced influenza-related hospitalization and death (Hamborsky et al., 2015).
Live-Attenuated Influenza Vaccines (LAIV)
LAIV was approved in the United States in 2003. The LAIV and IIV contain the
same influenza viruses each season as determined by the World Health Organization
annually. LAIV contains cold-adapted, weakened influenza viruses that confer immunity
by replication in the nasopharynx (Lanthier et al., 2011). Rather than an injection used for
IIV, the LAIV is administered from a single-dose sprayer unit, half of the dose is sprayed
into each nostril (MedImmune, 2016). LAIV is approved for use in healthy patients from
2 to 49 years of age (Hamborsky et al., 2015).
Varied Seasonal Efficacy
How well the flu vaccine work depends on multiple factors and can change
seasonally. Significant factors contributing to vaccine effectiveness are characteristics of
the individuals being vaccinated like age, health status, and time of vaccination during
the flu season (Rhorer et al., 2009). In addition, the viruses chosen for the vaccine are
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most effective when they are similar to the circulating flu viruses in the community
(CDC, 2014). Due to these variables determining influenza effectiveness is challenging
and requires annual evaluation to determine the most effective means of protecting the
population from the flu virus.
Hemagglutinin and neuraminidase are surface antigens located on the influenza
virus that can be identified by the immune system if previous exposure has produced the
correct antigens (Rhorer et al., 2009; Sultana et al., 2014). The influenza virus alters these
surface proteins to escape detection in the host resulting in an illness called antigenic
drift. Antigenic drift is a minimal alteration in surface antigens where antibodies from
exposure to previous similar strains may provide partial immunity (Hamborsky et al.,
2015). Antigenic shift also results in host illness when two influenza viruses share genetic
information to produce a new influenza strain unknown to the host immune system.
Antigenic shift tends to be more virulent in the population because the virus is completely
unknown to the immune system (Hamborsky et al., 2015). Table 1 shows vaccine
effectiveness estimates from 2014-2017 (Chung et al., 2016; Flannery & Chung, 2016;
Flannery et al., 2017).
Table 1
U.S. Flu Vaccine Effectiveness Estimates for 2014-2017
2014-2015
2015-2016
2016-2017
Adjusted
Adjusted
Adjusted
Age
VE %
95% CI
VE %
95% CI
VE %
95% CI
6 mo-8 yr
25
(6 to 40)
48
(31 to 61)
61
(49 to 70)
9-17
25
(2 to 42)
64
(44 to 77)
35
(13 to 61)
Note. VE = vaccine efficacy. Adjusted for age, sex, race/ethnicity, self-rated general
health status, days from illness onset to enrollment, and calendar time of illness onset.
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Discontinued Live-Attenuated Vaccine and Advisory Committee on Immunization
Practices Recommendations
Vaccine recommendations in the United States are developed annually by the
Advisory Committee on Immunization Practices. An intranasal cold-adapted, LAIV was
first approved for use in the United States in 2003 (Rose et al., 2014). In September 2007,
the U.S. Food and Drug Administration expanded the indication for use in individuals 2
to 49 years of age, from the previous 5 to 49 years of age indication (Hamborsky et al.,
2015).
In June 2016, data from four observational studies evaluating influenza vaccine
effectiveness in the pediatric population during the 2015-2016 influenza season was
presented to the ACIP (Flannery & Chung, 2016). The two studies conducted in the U.S.
showed decreased effectiveness of LAIV compared to IIV (Grohskopf et al., 2016). For
the 2015-2016 U.S. flu season the Influenza Vaccine Effectiveness Network “showed no
significant vaccine effectiveness among children aged 2 through 17 years for LAIV for
all influenza A and B viruses combined (3%; 95% CI = -49–37) or for influenza
A(H1N1) (-21%; 95% CI = -108–30)”(Grohskopf et al., 2016), Studies carried out by
MedImmune (LAIV manufacturer), the United Kingdom (35%; 95% CI: -29.9 to 67.5),
and Finland (51%; 95% CI: 28 to 66%) showed the statistically significant efficacy of
LAIV against all influenza strains (Matrajt, Halloran, & Antia, 2018). These studies
showed LAIV and IIV effectiveness comparable to vaccine effectiveness observational
studies in prior seasons.
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Herd Immunity and Children
Increasing the number of children immunized against the flu also increases herd
immunity defined by the indirect protection of household and community members that
are unable to receive the vaccine, or that may be at high risk for adverse flu-related
outcomes (Lind et al., 2014). Children tend to experience higher attack rates of annual
influenza than other populations and gain more complete protection from flu vaccinations
making them the ideal target population to slow transmission in the community or reduce
incidence among population segments that may be at risk of severe consequences of
infection (Fine, Eames, & Heymann, 2011).
High vaccination coverage reduces exposure of unvaccinated persons to infection,
resulting in indirect protection in addition to direct protection for the those vaccinated
(Glezen, Gaglani, Kozinetz, & Piedra, 2010). The direct effect of immunity reduces
infection rates among vaccinated individuals resulting in less infection circulating in the
community, less influenza exposure, resulting in herd immunity by indirect means (Fine
et al., 2011). Increasing the number of school-age children immunized against the flu also
increases herd immunity by the indirect protection of household and community
members (Lind et al., 2014).
Uptake in the Community
Annual surveillance and vaccine effectiveness research are conducted to improve
influenza vaccines, anticipate seasonal virus strains, and track the circulation of the of
influenza in the community (Kelly et al., 2009). Previous clinical trials of LAIV in young
children have shown it to be highly effective (Belshe et al., 2007). Initial studies
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comparing LAIV and IIV efficacy in young children found LAIV to be more effective in
preventing the flu in children 2-8 years of age. Subsequent studies have had conflicting
results with the diminished effectiveness of the LAIV across all circulation influenza
virus as opposed to IIV.
Over half of all flu vaccines in the U.S. are administered to individuals ages 6
months to 17 years old (Peng-jun Lu et al., 2013). Studies addressing flu vaccination
barriers cite time off work, cost, and lack of convenience as determining factors in
vaccinating school children for the flu. According to the Morbidity and Mortality Weekly
Report, the United States vaccination coverage is consistently below the Healthy People
2020 goal of 70 % (Peng-jun Lu et al., 2013).
In addition to the reported inconsistencies in flu vaccine efficacy, annual
influenza immunization recommendations have varied in children 2-8 years of age.
Inconsistencies in vaccine recommendations can negatively impact vaccine uptake in the
community by diminishing the patients perceived benefits of following vaccine
recommendations (Mueller, Hill, Fontanesi, & Kopald, 2007). Studies show parents who
delayed and refused vaccine doses were more likely to have vaccine safety concerns and
perceive fewer benefits associated with these vaccines (Blyth et al., 2014; Cheney &
John, 2013; Smith et al., 2011).
Socioeconomic and Demographic Factors
Socioeconomic and demographic factors have the potential to influence the
outcome of a study by an indication of a relationship among variables where one does not
truly exist. For this study, four variables have been identified as factors that may
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influence vaccine uptake and choice among children in the United States population.
These factors include age, race, family income, and health insurance status.
Age. Age has been identified as a factor that may influence vaccine uptake due to
ACIP recommendations. The ACIP recommends influenza vaccination for all children 6
months to 18 years of age before the annual influenza season. While LAIV was approved
by the FDA for use in healthy patients from 2 to 49 years of age for previous seasons,
ACIP recommendations focused on children ages 2-8 years of age (Hamborsky et al.,
2015).
Race. Race has been identified as a factor that may also influence vaccine update
due to disparities in vaccine uptake among minorities in the United States. According to
Chen (2007), flu vaccine rates among five ethnic groups (White, Latino, African
American, Filipino American, and Japanese American) varied significantly. Among all
participants who indicated they were concerned about getting the flu, individuals
identified as White or African American were more likely to get vaccinated than Latino
Americans (Chen, Fox, Cantrell, Stockdale, & Kagawa-Singer, 2007). Latino American
were more likely to report access and cost as flu vaccination barriers, and African
Americans noted concerns regarding the safety of flu vaccines.
Family income. Family income has been identified as another factor that may
also influence vaccine update due to the time and cost associated with vaccination. A
study by Cohen (2012), noted more than 10 % of those who were not vaccinated reported
prohibitive cost as a reason. Another study indicated low pediatric inﬂuenza vaccination-
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acceptance rates of 40.8 % in family’s whose income was $40,000 or less annually
(Frew, Hixson, Rio, Esteves-Jaramillo, & Omer, 2011).
Health insurance status. Health insurance status has been identified as a
covariate due to its potential influence on cost and access barriers associated with
vaccination. According to Frew (2011), “children with private insurance were more likely
to be up-to-date with immunizations compared with those with public insurance or no
insurance although parents without health insurance indicated that they were more likely
to vaccinate their children against H1N1 than parents with health insurance.”
Definitions
Dependent Variable: Childhood influenza vaccination by type (LAIV or IIV)
Independent Variables: ACIP recommendations by flu seasons (2014-2015, 20152016, and 2016-2017). Socioeconomic and demographic factors that may contribute to
influenza vaccine type including; age, race, family income, and insurance status.
Advisory Committee on Immunization Practices (ACIP): A group of medical and
public health experts that develop recommendations annual influenza vaccination for all
persons 6 months of age and older in the United States (Harris et al., 2014).
Attack Rate: is the cumulative incidence of influenza virus infections in a defined
population (Jayasundara, Soobiah, Thommes, Tricco, & Chit, 2014).
Assumptions
The following assumptions are made about this study:
•

The study sample is representative of the population.
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•

Secondary information provided by the CDC and WHO is accurate and
timely.

•

Parent-administered surveys about their child’s influenza vaccination status
are accurate.

These assumptions are made because the data used for this study is secondary and
deviation from these factors cannot be controlled for through study design or primary
sampling.
Scope and Delimitations
The focus of this study is influenza vaccination rates of children ages 0 to 17
years of age in the United States; CDC reports for 2014-2015, 2015-2016, and 2016-2017
flu seasons. Studies show vaccination uptake (yes/no) varies among individuals based on
socioeconomic and demographic factors (Chen et al., 2007; Frew et al., 2011; Galarce,
Minsky, & Viswanath, 2011; Hamborsky et al., 2015). These factors will be evaluated as
they may also contribute to flu vaccine uptake by type (IIV/LAIV) in the community.
Socioeconomic and demographic status for this study included age, race, family income,
and health insurance status.
The delimitations of this study are:
•

Three influenza seasons; 2014-2015, 2015-2016, and 2016-2017

•

quantitative cross-sectional study

•

Including US population

•

Includes vaccination rates of children ages 0-17 years old.
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An issue of generalization may occur because the secondary data set uses limited
variables to define race among participants, where race identification is complex and may
not be consistent throughout the U.S. population.
Significance
The potential contribution of this study is to add to current knowledge regarding
influenza recommendations and influenza vaccine uptake among children. Most flu
vaccine research evaluates the efficacy of the vaccine based on a test-negative design (a
variation of the case-control design). Few studies evaluate influenza vaccine uptake by
type socioeconomic status, demographic characteristics, and ACIP recommendations.
This study aims to assess how socioeconomic and demographic status impacts vaccine
uptake for three consecutive flu seasons and how ACIP recommendations influence
LAIV uptake among children in the United States over the three most recent flu seasons.
Vaccination uptake is significantly influenced by social and psychological factors,
some of which are under-reported and poorly understood (Wheelock, Miraldo, Parand,
Vincent, & Sevdalis, 2014). Although structural barriers are known to limit vaccination
rates, social and psychological factors may also affect the decision to vaccinate children.
Perceptions about flu susceptibility and vaccine effectiveness significantly influence
vaccination adoption (Wheelock et al., 2014). Evaluating current procedures and policies
could improve patient perceptions and access.
Policies can directly influence the other levels by altering and influencing the
access and desire of flu vaccinations by making them unavailable, altering access,
reducing their perceived effectiveness, limiting affordability, or indicating belief of risk
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associated with their use. The discontinued ACIP recommendation of the LAIV has the
potential to negatively influence influenza vaccine uptake in general if the underlying
cause of LAIV’s reduced efficacy is not defined and addressed due to conflicting policy,
and inconsistent recommendations by governing bodies, local health departments, and
family practitioners. Improving vaccine recommendations and policy may lead to
increased vaccine uptake and result in fewer sick days, reduced suffering, increased
productivity, lower health cost and reduced illness and death associated with the flu virus
especially for those most at risk.
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Section 2: Research Design and Data Collection
Introduction
The purpose of this study was to examine the relationship between seasonal
influenza vaccination ACIP recommendations, socioeconomic status, demographic
characteristics, and vaccine uptake among children over three consecutive flu seasons.
The dependent variable was influenza vaccine type (LAIV and IIV) among U.S. children.
The independent variables were ACIP influenza vaccine recommendation by flu season
including flu seasons 2014-2015, 2015-2016, and 2016-2017 and socioeconomicdemographic status indicated by age, race, family income, and health insurance status.
The major sections of this chapter include research design, methodology, and threats to
validity. The chapter will also include discussion of the study population, sampling,
operational constructs, and ethical procedures.
Research Design and Rationale
This quantitative cross-sectional study included the NHIS secondary data reported
by the CDC for flu seasons 2014-2015, 2015-2016, and 2016-2017 to evaluate the
relationship between childhood influenza vaccination rates, ACIP recommendations,
socioeconomic factors, and demographic characteristics. This study design allowed for
timely analysis of a large dataset and is commonly used to assess policies and their
impact on community health. This type of analysis is also used to examine the
relationship between exposure and outcome prevalence in a defined population at a single
point in time (Oleckno, 2002). The cross-sectional research design also provided
advantages in being quick and easy to conduct because the data on selected variables are
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only collected once. Multiple exposures and outcomes can be measured simultaneously,
resulting in the ability to measure prevalence for all variables being studied in a specific
population (Oleckno, 2002).
Methodology
Population
The population for this study includes children residing in the United States over
three consecutive flu seasons including 2014-2015, 2015-2016, and 2016-2017. The
sample population for influenza vaccinations is provided by the NHIS. The NHIS survey
is conducted from October through June each year for children 0 to 17 years of age.
NHIS data are used to assess annual flu vaccination coverage by age at the national, state,
and selected local levels and estimates are based on the parent or guardian reported data
(CDC, 2017). Table 2 describes the variables used in this study.
Table 2
Study Variables
Variables
Dependent

Description
Flu vaccine status

Inclusion criteria
LAIV, IIV

Variable type
Nominal/Categorical

Independent

ACIP
recommendation

Flu seasons 2014-2015, 20152016, and 2016-2017

Nominal/Categorical

Age

Under a year old to 17 years of
age

Nominal/Categorical

Race

White, Black, Hispanic, Asian,
Other

Nominal/Categorical

Family income

$0 - $34,999, $35,000 $74,999, $75,000 - $99,999,
$100,000 and over

Nominal/
Categorical/Ordinal
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Health insurance
status

Private, Medicaid and other
public, other coverage,
uninsured

Nominal/Categorical

Year

2014-2015, 2015-2016, 20162017

Nominal/Categorical

Sampling and Sampling Procedures
Secondary surveillance data provided by the CDC were used in this study based
on the NHIS, which is a cross-sectional household interview survey targeting the civilian
noninstitutionalized population in the United States (CDC, 2018). The NHIS is conducted
as a face-to-face interview, stratified by each U.S. state and the District of Columbia
(CDC, 2018). Data are collected continuously throughout the year by The U.C. Census
interviewers. The NHIS is conducted using computer-assisted personal interviewing,
which guides the interviewer through the questionnaire where the interviewer enters
responses into the computer (CDC, 2018). Subsequent survey questions are based on
answers to previous questions, and the responses data is automatically saved in the survey
data file (CDC, 2018).
For each household with children, a sample adult 18 and over and a sample child
under the age of 17 are randomly chosen to participate in the survey (CDC, 2018). In
addition, the NHIS sample design oversamples non-White individuals to make sure all
races are represented in the study. Information about the sample child is acquired from an
adult residing in the household who is knowledgeable about the child’s health (CDC,
2018).
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All individual identifying information collected by the NHIS is held confidential
and such information is not disclosed or released to anyone for any other purpose without
the consent of the respondent (CDC, 2018). The National Center for Health Statistics
must adhere to Section 308(d) of the Public Health Service Act (42 U.S.C. 242m) and the
Confidential Information Protection and Statistical Efficiency Act (44 U.S.C. 3501 note)
to protect the privacy of participants (National Center for Health Statistics, 2015b, 2016b,
2017b).
Sample Size
According to the NHIS, the sample size can vary from year to year. The publicly
released NHIS data files for 2015 contain data for 41,493 households, including 42,288
families, 103,789 persons, and 12,291 children (National Center for Health Statistics,
2015b). Additionally, according to the National Center for Health Statistics,
The 2015 conditional response rate for the Sample Child component was 91.4 %,
which was calculated by dividing the number of completed Sample Child
interviews (12,291) by the total number of eligible sample children (13,444). The
unconditional or final response rate of 63.4 % for the Sample Child segment was
calculated by multiplying the conditional rate of 91.4 % by the final family
response rate of 69.3 % (National Center for Health Statistics, 2015a, p.16).
Of the 12,291 children surveyed for the 2014-2015 flu season, 5,847 (47.57 %) were
vaccinated for the flu (National Center for Health Statistics, 2015a). According to NHIS
data, 4,252 (74.79%) received the shot, and 1,369 (24.08%) received the nasal mist
(National Center for Health Statistics, 2015a).
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The publicly released data files for the 2016 NHIS contain data for 40,220
households containing 40,875 families, 97,169 persons, and 11,107 children (National
Center for Health Statistics, 2016b). Additionally,
The conditional response rate for the Sample Child component was 92.3 %. The
unconditional or final response rate of 61.9 %, for the Sample Child segment, was
calculated by multiplying the conditional rate of 92.3 % by the final family
response rate of 67.1 %. (National Center for Health Statistics, 2016b, p. 15).
Of the 11,107 children surveyed for the 2015-2016 flu season, 5,299 (47.70%) were
vaccinated for the flu (National Center for Health Statistics, 2016b). According to NHIS
data, 4,099 (78.90%) received the shot, and 1,038 (19.98%) received the nasal mist
(National Center for Health Statistics, 2016b).
The publicly released data files for the 2017 NHIS contain data for 32,617
households containing 33,157 families, 78,543 persons, and 8,845 children (National
Center for Health Statistics, 2017b). Further,
The conditional response rate for the Sample Child component was 92.1 %, which
was calculated by dividing the number of completed Sample Child interviews
(8,845) by the total number of eligible sample children (9,601). The unconditional
or final response rate of 60.6 % for the Sample Child segment was calculated by
multiplying the conditional rate of 92.1% by the final family response rate of
65.7% (National Center for Health Statistics, 2017b, p. 15).
Of the 8,845 children surveyed for the 2016-2017 flu season, 4,024 (45.49 %) were
vaccinated for the flu (National Center for Health Statistics, 2017b). According to NHIS
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data, 3571 (91.24%) received the shot, and 293 (7.49%) received the nasal mist (National
Center for Health Statistics, 2017b).
The sample for this study includes 13,347 children ages 0-17 residing in the
United States. These cases were chosen based on the data provided; children who did not
receive the flu vaccine were excluded from the sample. Additional cases that did not have
responses for all independent variables were also excluded.
Instrumentation and Operationalization of Constructs
The NHIS data are used to examine annual influenza coverage of children ages 0
to 17 years of age. Data used for this study are provided by the CDC, are open use, and
include all study variables (National Center for Health Statistics, 2015a, 2016a, 2017a).
Study Variables
Dependent variable. The dependent variable was influenza vaccination type
among children ages 0-17 years of age for each flu season, where IIV is coded as 1, and
LAIV coded as 2. Table 3 includes description and coding for the dependent variables.
Table 3
Dependent Variable Descriptions
Variable name
CSHSPFL1
2014-2015

Description and coding
Was this a shot, or was it a
vaccine sprayed in the nose?

Variable type
nominal

Study code
0 Flu shot
1 Flu nasal spray or
“LAIV.”

CSHSPFL1
2015-2016

Was this a shot, or was it a
vaccine sprayed in the nose?

nominal

0 Flu shot
1 Flu nasal spray or
“LAIV.”

CSHSPFL1
2016-2017

Was this a shot, or was it a
vaccine sprayed in the nose?

nominal

0 Flu shot
1 Flu nasal spray or
“LAIV.”
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Note. Data Source: NHIS, 2015, 2016, and 2017. Exclude CSHSPFL1 (7 = Refused, 8 =
Not ascertained, and 9 = Don’t know)
Independent variables. Independent variables include year (Research Question 4
only), age, race, family income, and health insurance status (Research Questions 1-3
only). Age was recoded into categorical variables to include children younger than 1 year
of age in the analysis. Table 4 includes description and coding for the independent
variables.
Table 4
Independent Variable Descriptions
Variable
AGE_P
(Research
Question 1-3)

Description and coding
Age

Variable type
Nominal

Study code
(1) 0-2
(2) 3-5
(3) 6-8
(4) 9-11
(5) 12-14
(6) 15-17

HISCODI3
(Research
Question 1-3)

Race

Nominal

(1) Hispanic
(2) White
(3) Black
(4) Asian
(5) All other race groups

INCGRP5
(Research
Question 1-3)

Total combined family
income (grouped)

Nominal

(1) $0 -$34,999
(2) $35,000 - $74,999
(3) $75,000 - $99,999
(4) $100,000 and over

COVER
(Research
Question 1-3)

Health insurance
coverage

Nominal

(1) Private
(2) Medicaid and other public
(3) Other coverage
(4) Uninsured

YEAR
(Research
Question 4)

Data year

Nominal

(1) 2015
(2) 2016
(3) 2017

Note. Data Source: NHIS, 2015, 2016, and 2017.
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Data Analysis Plan
IBM SPSS Statistics version 24 and SAS student edition software packages were
used for the statistical analysis of this study. Binary logistic regression was employed to
explore the relationship between influenza vaccination type, age, race, family income,
and health care status for Research Questions 1-3. Data from three consecutive flu
seasons were combined for Research Question 4; cases with missing variables were
excluded. Calculations include descriptive statistics on the tested association between
ACIP recommendations, vaccine type, and socioeconomic-demographic status. Data for
all three consecutive flu seasons were publicly reported by the CDC. The influenza
season time periods are based on historical data provided by the CDC.
Analysis Plan for Each Research Question
Research Question 1: What is the relationship between age, race, family income,
health insurance status, and vaccine type (LAIV/ IIV) among U.S. children for flu season
2014-2015?
H01: There is no relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 20142015.
Ha1: There is a relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 20142015.
The independent variables were age, race, family income, and health insurance
status. The dependent variables were vaccine type (LAIV/IIV) for this research question.
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These variables are part of the NIS secondary data set provided by the CDC. Descriptive
will be utilized to identify outliers and distribution. Binary logistic regression analysis
between socioeconomic-demographic status and flu vaccine type for flu season 20142015 will be used to test this hypothesis. A P-value < 0.05 indicates rejection of the null
hypothesis.
Research Question 2: What is the relationship between age, race, family income,
health insurance status, and vaccine type (LAIV/ IIV) among U.S. children for flu season
2015-2016?
H02: There is no relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 20152016.
Ha2: There is a relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 20152016.
The independent variables were age, race, family income, and health insurance
status. The dependent variables were vaccine type (LAIV/IIV) for this research question.
These variables are part of the NIS secondary data set provided by the CDC. Descriptive
will be utilized to identify outliers and distribution. Binary logistic regression analysis
between socioeconomic status, demographic characteristics, and flu vaccine type for flu
season 2015-2016 will be used to test this hypothesis. A P-value < 0.05 indicates
rejection of the null hypothesis.
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Research Question 3: What is the relationship between age, race, family income,
health insurance status, and vaccine type (LAIV/ IIV) among U.S. children for flu season
2016-2017?
H03: There is no relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 20162017.
Ha3: There is a relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 20162017.
The independent variables were age, race, family income, and health insurance
status. The dependent variables were vaccine type (LAIV/IIV) for this research question.
These variables are part of the NHIS secondary data set provided by the CDC.
Descriptive will be utilized to identify outliers and distribution. Binary logistic regression
analysis between socioeconomic status, demographic characteristics, and flu vaccine type
for flu season 2016-2017 will be used to test this hypothesis. A P-value < 0.05 indicates
rejection of the null hypothesis.
Research Question 4: What is the relationship between influenza vaccine type
(LAIV/IIV) of U.S. children and ACIP recommendations indicated by flu seasons 20142015, 2015-2016, and 2016-2017?
H04: There is no relationship between influenza vaccine type (LAIV/IIV) of U.S.
children and ACIP recommendations indicated by flu seasons 2014-2015 (LAIV
preferred), 2015-2016 (LAIV & IIV) and 2016-2017 (IIV preferred).
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Ha4: There is a relationship between influenza vaccine type (LAIV/IIV) of U.S.
children and ACIP recommendations indicated by flu seasons 2014-2015, 20152016, and 2016-2017.
The independent variable is ACIP recommendations, and the dependent variable
is vaccine type. These variables are part of the NHIS secondary data set provided by the
CDC. The chi-square test of homogeneity will be used to determine if a difference exists
between the binomial proportions of three independent groups (flu season) on a
dichotomous dependent variable (vaccine type). This test will be used to determine
whether the proportions are statistically significant between groups indicated by flu
season. A P-value < 0.05 indicates rejection of the null hypothesis. If there are
statistically significant differences in proportions, a post hoc test will determine how
these groups differ.
Threats to Validity
Content validity is defined by the inclusion of all the characteristics of the
construct being measured (Frankfort-Nachmias & Nachmias, 2008). Type I sampling
error is a false positive while a type II sampling error is a false negative result in
hypothesis testing (Oleckno, 2002). Therefore, a type I error detects an association that is
not present, and a type II error is failing to identify a positive relationship. Type I
sampling error is measured by the p-value; a high p-value indicates a potential sampling
error resulting in a false association. P values less than 0.05 are statistically significant
and determined by the alpha level (Blair & Taylor, 2008). A substantial sample size
increases the chance for statistical significance. Type II sampling error is measured by the
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beta level. The smaller the beta level, the higher the statistical power. The beta level is
also affected by the sample size, the larger the sample, the less likely for a type II error.
Confidence intervals that are narrow suggest the associations are precise (Blair & Taylor,
2008). The survey data for this study provides a large sample size and reduces the risk of
Type I or II error.
Reliability is determined by a measurements ability to provide similar results in
subsequent tests, calculation of standard deviation can account for the variance in
collected data. Standard deviation is used for quantifying the dispersion of a set of data
values (Oleckno, 2002). Test results will vary from person to person falling within a bell
cover with most cases located near the mean. A small standard deviation indicates that
the data points tend to be close to the mean, reflecting increased reliability (Blair &
Taylor, 2008). A high standard deviation indicates a lack of consistency with results
spread out over a wide range of values. The standard deviation is also used to measure
confidence in the statistical conclusions of a study and provide the likelihood of values
falling within the same range if the same study is repeated (Blair & Taylor, 2008).
Confidence intervals will be reported in the final analysis to show the reliability of study
results.
An issue of generalization may occur because the secondary data set uses limited
variables to define race among participants, where race identification is complex and may
not be consistent throughout the U.S. population. Other factors may influence vaccine
uptake beyond those in the scope of this study resulting in a potential type I or II error.
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The Strengths and Limitations of these Measurements
Cross-sectional quantitative research investigates the relationship between
variables in their natural environment rather than a laboratory setting (Polit & Hungler,
1999). This type of investigation often utilizes data from descriptive studies to formulate
hypotheses, determine a relationship between variables, and test theories. A Crosssectional study evaluates the nature of relationships that exist and does not infer causality,
like traditional experimental studies (Creswell, 2012).
The data from the NHIS survey is cross-sectional, based on an annual sample
representing a changing cohort of subjects (CDC, 2015). In this case, the NHIS does not
collect information from all subgroup populations omitting institutionalized individuals
including military families. This data is secondary, so the health information collected
does not include verifiable medical data or laboratory data (Rolnick et al., 2013). Some
survey respondents may not be forthcoming about a behavior many consider to be
undesirable. It is important to take into account the limitations inherent in self-reported
data, including but not limited to reembrace error, reporting bias, incorrect
documentation, and loss of cases.
One of the greatest limits to measuring a relationship among variables is the
assumption of generalizability (Creswell, 2012). While statistical analysis of data sets
may reveal that two variables tend to vary together, it does not mean they actually do. If
the data is not representative of the real population, study results could indicate a
relationship among variables that does not truly exist in the actual population. There are a
number of unknown factors called confounders that can be unaccounted for resulting in a
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false perception of a relationship among variables (Oleckno, 2002). In this study,
potential confounders will be evaluated to try and control for these factors. Other
unknown factors could also contribute to confounding but are not addressed in this study.
Ethical Procedures
No ethical issues were identified in this study. None of the individuals surveyed
are identified in the data provided by the CDC. According to the CDC (2017),
“Information collected in the National Immunization Surveys is used only for reporting
important statistical information about health issues.” By law sensitive information like
name, address or telephone number about any specific individual are not publicly
available, and the CDC abides by these regulations. No efforts will be used to identify
cases, only public use data will be used for this study, and all data will be kept on a
password protected computer not shared on a network. Institutional review board (IRB)
approval will be obtained prior data analysis to confirm that patient privacy is protected.

36
Section 3: Presentation of the Results and Findings
Introduction
The purpose of this study was to examine the relationship between seasonal
influenza vaccination ACIP recommendations, socioeconomic status, demographic
characteristics, and vaccine uptake among children over three consecutive flu seasons.
The dependent variable was influenza vaccine type (LAIV and IIV) among U.S. children.
The independent variables were ACIP influenza vaccine recommendation by flu season
including flu seasons 2014-2015, 2015-2016, and 2016-2017 and socioeconomicdemographic status indicated by age, race, family income, and health insurance status.
Research Question 1: What is the relationship between age, race, family income,
health insurance status, and vaccine type (LAIV/ IIV) among U.S. children for flu season
2014-2015?
H01: There is no relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2014-2015.
Ha1: There is a relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2014-2015
Research Question 2: What is the relationship between age, race, family income,
health insurance status, and vaccine type (LAIV/ IIV) among U.S. children for flu season
2015-2016?
H02: There is no relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2015-2016.
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Ha2: There is a relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2015-2016.
Research Question 3: What is the relationship between age, race, family income,
health insurance status, and vaccine type (LAIV/ IIV) among U.S. children for flu season
2016-2017?
H03: There is no relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2016-2017.
Ha3: There is a relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2016-2017.
Research Question 4: What is the relationship between influenza vaccine type
(LAIV/IIV) of U.S. children and ACIP recommendations indicated by flu seasons 20142015, 2015-2016, and 2016-2017?
H04: There is no relationship between influenza vaccine type (LAIV/IIV) of U.S.
children and ACIP recommendations indicated by flu seasons 2014-2015 (LAIV
preferred), 2015-2016 (LAIV & IIV) and 2016-2017 (IIV preferred).
Ha4: There is a relationship between influenza vaccine type (LAIV/IIV) of U.S.
children and ACIP recommendations indicated by flu seasons 2014-2015, 2015-2016,
and 2016-2017.
The major sections of this chapter include data collection and the results of the
study. The chapter will also include frequencies, population representation, hypothesis
analysis, and a summary of the findings.
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Data Collection and Secondary Dataset
Vaccination rates are documented annually by the CDC, which also involved the
ACIP, a group of public health and medical experts who make vaccine recommendations
updated annually to reflect continued research and development (Harris et al., 2014). The
CDC uses multiple methods to document and surveys vaccination rates for vaccines
recommended by the ACIP. In this cross-sectional study, secondary surveillance data
provided by the CDC, from the NHIS, were used. The NHIS is a cross-sectional
household interview survey targeting the civilian noninstitutionalized population residing
in the United States (CDC, 2018). The NHIS is conducted as a face-to-face interview,
stratified by each U.S. state and the District of Columbia (CDC, 2018). The U.S. Census
Bureau is the data collection agency for the NHIS, and data are collected continuously
throughout the year by census interviewers. According to the National Health Survey,
The sampling plan follows a multistage area probability design of clusters of
addresses that are located in primary sampling units (PSU’s). A PSU consists of a
county, a small group of contiguous counties, or a metropolitan statistical area.
The NHIS sample is divided into four separate panels, so each panel is a
representative sample of the U.S. population. This design feature has a number of
advantages, including flexibility for the total sample size.
The NHIS includes the noninstitutionalized civilian population residing in the
United States at the time of the interview (National Center for Health Statistics, 2015b,
2016b, 2017b). Individuals excluded from the survey include long-term care facility
patients, individuals on active duty with the Armed Forces, incarcerated persons, and
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U.S. nationals living outside the U.S (National Center for Health Statistics, 2015b, 2016a,
2017b). For the family core component, adult members of the household available at
interview time are invited to participate. For each household with children, a sample
adult 18 years of age and over and a sample child under the age of 17 is randomly chosen
to participate in the survey (CDC, 2018). In addition, the NHIS sample design
oversamples non-White individuals to make sure all races are represented in the study.
Information about the sample child is acquired from an adult residing in the household
who is knowledgeable about the child’s health (CDC, 2018).
The NHIS is conducted using computer-assisted personal interviewing (National
Center for Health Statistics, 2015b, 2016b, 2017b). The computer-assisted personal
interviewing data collection method includes computer software that guides the
interviewer through the questionnaire where the interviewer enters responses into the
computer (CDC, 2018). Subsequent survey questions are based on answers to previous
questions, and the responses data is automatically saved in the survey data file (CDC,
2018).
Participation in the survey is voluntary, and the confidentiality of responses is
guaranteed under Section 308(d) of the Public Health Service Act (CDC, n.d.).
Additionally, the National Center for Health Statistics must adhere to Section 308(d) of
the Public Health Service Act (42 U.S.C. 242m) and the Confidential Information
Protection and Statistical Efficiency Act (44 U.S.C. 3501 note) to protect the privacy of
participants (National Center for Health Statistics, 2015b, 2016b, 2017b). The annual
response rate of NHIS is roughly 70% of the qualified households in the sample (CDC,
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2018). All individual identifying information collected by the NHIS is held confidential,
and personal information is not disclosed or released to anyone without the consent of the
respondent (CDC, 2018).
Baseline Descriptive and Demographic Characteristics
For the 2014-2015 flu season a total of 5,097 children received the flu vaccine,
3,832 (75.2%) received the flu shot, and 1,265 (24.8%) the LAIV. The age range of
children in the study was 0-17 years of age. Most participants for this flu season were
covered by health insurance (96.8%) either private or public, and only 3.2% were
uninsured. The largest ethnic group for this flu season was White individuals at 48.7% of
the total population and “All Other Race Groups” was the least at 1.8% of the population.
For the 2014-2015 flu season, family income ranged from $0-100,000+, with the largest
population at the lowest and highest income groups. Table 5 includes socioeconomic
status and demographic frequencies for the 2014-2015 flu season.
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Table 5
2014-2015 Socioeconomic and demographic Frequency Table
Characteristics
Frequency
Age
0-2
860
3-5
946
6-8
874
9-11
818
12-14
828
15-17
771
Total
5097
Insurance
Private
2793
Medicaid and Other
2025
Public
Other Coverage
114
Uninsured
165
Total
5097
Race
Hispanic
1480
White
2480
Black
644
Asian
402
All Other Race Groups
91
Total
5097
Family Income
$0-$34,999
1623
$35,000-$74,999
1389
$75,000-$99,999
592
$100,000 +
1493
Total
5097
Note. Data Source: NHIS, 2015.

Percent

Cumulative Percent

16.9
18.6
17.1
16.0
16.2
15.1
100.0

16.9
35.4
52.6
68.6
84.9
100.0

54.8
39.7

54.8
94.5

2.2
3.2
100

96.8
100

29.0
48.7
12.6
7.9
1.8
100

29.0
77.7
90.3
98.2
100

31.8
27.3
11.6
29.3
100

31.8
59.1
70.7
100
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For the 2015-2016 flu season a total of 5,676 children received the flu vaccine,
3,766 (66.3%) received the flu shot, and 1,910 (33.7 %) LAIV. The age range of children
in the study was 0-17 years of age. Most participants for this flu season had health
coverage (97.1%) either private or public, and only 2.9% were uninsured. The largest
ethnic group for the 2015-2016 flu season was White at 56.7% of the total population,
and “All Other Race Groups” was the least at 2.4% of the population. Family income for
2016 ranged from $0-100,000+, with the largest population at the second lowest and
highest income groups. Table 6 includes socioeconomic and demographic frequencies for
the 2015-2016 flu season.
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Table 6
2015-2016 Socioeconomic and Demographic Frequency Table
Characteristics
Frequency Percent Cumulative Percent
Age
0-2
876
15.4
15.4
3-5
1099
19.4
34.8
6-8
990
17.4
52.2
9-11
917
16.2
68.4
12-14
941
16.6
85.0
15-17
853
15.0
100.0
Total
5676
100.0
Insurance
Private
3363
59.2
59.2
Medicaid and Other Public
1961
34.5
93.8
Other Coverage
189
3.3
97.1
Uninsured
163
2.9
100
Total
5676
100
Race
Hispanic
1216
21.4
21.4
White
3217
56.7
78.1
Black
679
12.0
90.1
Asian
428
7.5
97.6
All Other Race Groups
136
2.4
100
Total
5676
100
Family Income
$0-$34,999
1460
25.7
25.7
$35,000-$74,999
1503
26.5
52.2
$75,000-$99,999
746
13.1
65.3
$100,000 +
1967
34.7
100
Total
5676
100
Note. Data Source: NHIS, 2016.
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For the 2016-2017 flu season a total of 3,795 children received the flu vaccine,
3,263 (86.0%) received the flu shot, and 532 (14%) the LAIV. The age range of children
in the study was 0-17 years of age. Most participants for this flu season had health
coverage (97.3%) either private or public, and only 2.7% were uninsured. The largest
ethnic group for the 2016-2017 flu season was White individuals at 56.3% of the total
population, and “All Other Race Groups” was the least at 2.1% of the population. Family
income for 2017 ranged from $0-100,000+, with the largest population at the second
lowest and highest income groups. Table 7 includes socioeconomic and demographic
frequencies for the 2016-2017 flu season.
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Table 7
2016-2017 Socioeconomic and Demographic Frequency Table
Characteristics
Frequency Percent Cumulative Percent
Age
0-2
621
16.4
16.4
3-5
665
17.5
33.9
6-8
677
17.8
51.7
9-11
606
16.0
67.7
12-14
628
16.5
84.2
15-17
598
15.8
100.0
Total
3795
100.0
Insurance
Private
2262
59.6
59.6
Medicaid and Other Public
1277
33.6
93.3
Other Coverage
155
4.1
97.3
Uninsured
101
2.7
100
Total
3795
100
Race
Hispanic
852
22.5
22.5
White
2137
56.3
78.8
Black
437
11.5
90.3
Asian
290
7.6
97.9
All Other Race Groups
79
2.1
100
Total
3795
100
Family Income
$0-$34,999
946
24.9
24.9
$35,000-$74,999
969
25.5
50.5
$75,000-$99,999
426
11.2
61.7
$100,000 +
1454
38.3
100
Total
3795
100
Note. Data Source: NHIS, 2017.
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For all three seasons (2015, 2016, and 2017) a total of 32,243 children ages 0-17
were included in the data set. Of those children, 15,170 (48.6%) children ages 0-17
received the flu vaccine, and 16,052 (51.4%) did not receive the flu vaccine. According
to the NHIS survey data, 11,922 (81.5%) received the flu shot, and 2,700 (18.5 %)
received the flu nasal spray combined over all three flu seasons.
Statistical Assumptions
Research Questions 1-3: Binomial Logistic Regression
The assumptions of a binomial logistic regression provide information on the
accuracy of the predictions, test how well the regression model fits the data, determine
the variation in the dependent variable explained by the independent variables, and test
hypotheses on the regression equation (Laerd Statistics, 2015). The assumptions for this
study were:
•

Assumption #1: One dependent variable that is dichotomous (LAIV and IIV)

•

Assumption #2: One or more independent variables that are measured on
either a continuous or nominal scale (age, race, health insurance status, family
income).

•

Assumption #3: Independence of observations and the categories of the
dichotomous dependent variable and all your nominal independent variables
should be mutually exclusive and exhaustive. Independence of observations is
largely a study design issue rather than something you can test for using SPSS
Statistics.
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•

Assumption #4: A bare minimum of 15 cases per independent variable,
although some recommend as high as 50 cases per independent variable.

•

Assumption #5: A linear relationship between the continuous independent
variables and the logit transformation of the dependent variable. This research
question does not include continuous variables, so a linear relationship is not
necessary between variables.

•

Assumption #6: Data must not show multicollinearity, correlation coefficients
and Tolerance/VIF values found no multicollinearity among variables.

•

Assumption #7: No significant outliers, high leverage points or highly
influential points. No significant outliers were identified.

Research Question 4: Chi-Square Test of Homogeneity Statistical Assumptions
The chi-square test of homogeneity is used to determine if a difference exists
between the binomial proportions of three or more independent groups on a dichotomous
dependent variable. It will let you determine whether the proportions are statistically
significantly different in the different groups. If there are statistically significant
differences in proportions, a post hoc test to determine where the differences between
these groups lie can be used (Laerd Statistics, 2017).
•

Assumption #1: One dependent variable that is measured at the dichotomous
level (LAIV/ IIV).

•

Assumption #2: One independent variable that is polytomous, Flu vaccine
years (2015, 2016, and 2017).
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•

Assumption #3: Independence of observations, which means that there is no
relationship between the observations in each group of the independent
variable. Participants for each year were different based on the sampling
method identified by the NHIS.

•

Assumptions #4: Study type includes random sampling from three or more
independent populations. Each year was a different subset of the population.

•

Assumptions #5: A sufficiently large sample size so that the approximation to
the chi-squared distribution is valid. The sample size includes a total of 13,347
children ages 0-17.
Results

Data Analysis Research Question 1
Research Question 1: What was the relationship between age, race, family
income, insurance status, and vaccine type (LAIV/ IIV) among U.S. children for flu
season 2014-2015?
H01: There is no relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2014-2015.
Ha1: There is a relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2014-2015
Analysis of the 2014-2015 flu season. A 2-step procedure was used to assess the
relationship of age, race, health insurance status and family income on vaccine uptake
(LAIV vs. IIV). The first step used a Pearson’s chi-squared cross-tabulation to assess
how each independent variable by itself was distributed between vaccine type. This was
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used to provide a preliminary look at any potential imbalances across vaccine type. The
second step employed binomial logistic regression to assess the impact of the
independent variables when evaluated together.
An odds ratio is calculated for each independent variable from the logistic
regression model. The odds ratio is a measure of association between an exposure and an
outcome (Szumilas, 2010) and the odds that the LAIV vaccine will be given based on a
particular characteristic (socioeconomic-demographic status), compared to the odds of
the LAIV vaccine being administered in the absence of that characteristic
(socioeconomic-demographic status; Szumilas, 2010). This provides the change in the
odds for each increase in one unit of the independent variable (Szumilas, 2010). Odds
ratios are used to compare the relative odds of the occurrence of the outcome of interest
(LAIV), given exposure to the variable of interest (socioeconomic-demographic status).
A 95 % confidence interval (CI) is used to estimate the precision of the odds ratio
(Szumilas, 2010). A large CI indicates a low level of precision and a small CI indicates a
higher precision of the odds ratio (Szumilas, 2010). Unlike the p-value, the 95 % CI does
not report a measure’s statistical significance rather the 95 % CI is often used as a proxy
for the presence of statistical significance if it does not include the null value of odds
ratio = 1 (Szumilas, 2010).
Tables 8-11 show how the socioeconomic and demographic variables are
distributed among vaccine recipients their impact on vaccine type. Overall, many more
patients received IIV compared to LAIV in the 2014-2015 flu season (75.2% vs. 24.8%).
Table 8 shows that the distributions of ages differed by vaccine type. In the IIV group,
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the percentage within each age category ranged from a low of 10.9 % (9-11year old) to a
high of 15.0 % (ages 0-2 years old) with an average age of 6-8. Within the LAIV group
the range of percentages within each age category range from a low of 7.4 % (0-2 years
of age) to a high of 24.7 % (6-8 years old) with an average age of 6-8.
Table 8
2014-2015 Age and Vaccine Type Frequencies
Vaccine type
Age

IIV
0-2
767 (20.0%)
3-5
672 (17.5%)
6-8
561 (14.6%)
9-11
557 (14.5%)
12-14
628 (16.4%)
15-17
647 (16.9%)
Total
3832 (75.2%)
Note. Data Source: NHIS, 2015.

LAIV
93 (7.4%)
274 (21.7%)
313 (24.7%)
261(20.6%)
200 (15.8%)
124 (9.8%)
1265 (24.8%)

Total
860 (16.9%)
946 (18.6%)
874 (17.1%)
818 (16.0%)
828 (16.2%)
771 (15.1%)
5097 (100.0%)

Table 9 describes insurance coverage by vaccine type. Most participants had some
type of insurance coverage (96.3% for IIV, 98.1% for LAIV). More participants receiving
IIV had public insurance compared to those receiving LAIV (41.6% vs. 33.9%) while the
opposite was true for those having private insurance (52.5% for IIV, 61.8% for LAIV).
Table 9
2014-2015 Health Coverage and Vaccine Type Frequencies

Health Coverage
Private
Medicaid and other public
Other Coverage
Uninsured
Total

Vaccine type
IIV
LAIV
2011(52.5%)
782 (61.8%)
1596 (41.6%)
429 (33.9%)
84 (2.2%)
30 (2.4%)
141 (3.7%)
24 (1.9%)
3832 (75.2%)
1265 (24.8%)

Total
2793 (54.8%)
2025 (39.7%)
114 (2.2%)
165 (3.2%)
5097 (100.0%)
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Note. Data Source: NHIS, 2015.
Table 10 describes the distribution of race which differed between vaccine type.
Most vaccine recipients were Hispanic (31.2%IIV, 22.6% LAIV) or White (45.7% IIV,
57.5% LAIV).
Table 10
2014-2015 Race and Vaccine Type Frequencies
Vaccine type
Race
IIV
LAIV
Hispanic
1194 (31.2%)
286 (22.6%)
White
1753 (45.7%)
727 (57.5%)
Black
500 (13.0%)
144 (11.4%)
Asian
314 (8.2%)
88 (7.0%)
All other race groups
71 (1.9%)
20 (1.6%)
Total
3832 (75.2%)
1265 (24.8%)
Note. Data Source: NHIS, 2015.

Total
1480 (29.0%)
2480 (48.7%)
644 (12.6%)
402 (7.9%)
91 (1.8%)
5097 (100.0%)

Table 11 describes family income. More IIV recipients were in the lowest income
group (33.7% vs. 26.2% for LAIV) while more recipients in the LAIV group were in the
highest income group (36.5% vs. 26.9% for IIV).
Table 11
2014-2015 Family Income and Vaccine Type Frequencies
Vaccine type
Family Income
IIV
LAIV
$0 - $34,999
1292 (33.7%)
331 (26.2%)
$35,000 -$74,999
1080 (28.2%)
309 (24.4%)
$75,000 -$99,999
429 (11.2%)
163 (12.9%)
$100,000 and over
1031 (26.9%)
462 (36.5%)
Total
3832 (75.2%) 1265 (24.8%)
Note. Data Source: NHIS, 2015.

Total
1623 (31.8%)
1389 (27.3%)
592 (11.6%)
1493 (29.3%)
5097 (100.0%)
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Logistic regression was used to describe the data and explain any relationship
between vaccine type and the independent variables (covariates). Logistic regression
using vaccine type (probability modeled as LAIV) was applied to assess the relationship
amongst age group, insurance type, race, family income.
A model containing all 4 covariates was run. Before interpreting the model, the
model containing covariates needs to be checked that at least 1 covariate is different from
0 by testing that the global null hypothesis=0. A p-value<0.0001 was obtained allowing
for rejection of this null hypothesis. This suggests that at least 1 covariate in the model is
different from 0. In addition, a goodness-of-fit statistic, the Hosmer-Lemeshow test, is
applied to the resulting model to check that the model is correctly specified, the data do
not conflict with the assumptions made by the model. The obtained p-value=0.344
suggests that we cannot reject the hypothesis that the fitted model is correct.
The reduced model was determined a better fit when health insurance status was
determined not significant through initial analysis. Table 13 shows the results of the
reduced logistic regression analysis used to address Research Question 1. The logistic
regression model was statistically significant, χ2(15) = 315.831, p = .000. The Wald test
of significance indicated that age (p = .000), race (p = .000), and family income (p =
.000) were all statistically significant in relation to LAIV uptake.
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Table 12
Logistic Regression Reduced Model Flu Season 2014-2015

B

S.E.

95% CI for
Exp(B)
Exp(B) Lower Upper

Wald
df Sig.
Age
198.965 5 .000
3-5
1.223 .132 85.877
1 .000 3.397
2.623 4.400
6-8
1.542 .131 137.614 1 .000 4.674
3.612 6.047
9-11
1.356 .134 102.453 1 .000 3.882
2.985 5.048
12-14
.967
.138 49.450
1 .000 2.630
2.009 3.444
15-17
.435
.148 8.641
1 .003 1.545
1.156 2.066
Race
30.495
4 .000
White
.421
.087 23.457
1 .000 1.523
1.285 1.806
Black
.181
.118 2.368
1 .124 1.199
.952
1.509
Asian
-.027
.145 .036
1 .851 .973
.732
1.293
Other race groups .196
.268 .535
1 .465 1.217
.719
2.058
Family income
26.992
3 .000
35,000-74,999
.041
.092 .197
1 .657 1.042
.869
1.249
75,000-99,999
.310
.117 7.001
1 .008 1.363
1.084 1.715
100,000+
.422
.093 20.468
1 .000 1.524
1.270 1.830
Constant
-2.535 .132 369.371 1 .000 .079
Note. Data Source: NHIS, 2015. Variable(s) entered on step 1: Age, Health coverage,

Race, Family Income. Comparison groups are age (0-2), Race (Hispanic), Family income
($0-34,999), and health coverage (private).
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In the full model three of the four covariates are significant (p < 0.05) with only
insurance coverage (p = 0.115) not statistically significant. As a result, a reduced model
eliminating insurance coverage from the model was run. The Hosmer-Lemeshow statistic
from the reduced model was p = 0.393 suggesting a slightly better fit to the data. As a
result, inferences are based on this reduced model. The odds ratios are shown in Table 13.
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Table 13
2014-2015 Socioeconomic, Demographic, and Vaccine Type Odds Ratios
Odds Ratio Estimates and Wald Confidence Intervals
Independent Variables
Odds Ratio 95% Confidence Limits
Race
White vs. Hispanic
1.523
1.285
1.806
Black vs. Hispanic
1.199
0.952
1.509
Asian vs. Hispanic
0.973
0.732
1.293
All other races vs. Hispanic
1.217
0.719
2.058
White vs. Black
1.271
1.023
1.579
White vs. Asian
1.565
1.209
2.027
White vs. All other races
1.252
0.745
2.105
Black vs. Asian
1.232
0.900
1.686
Black vs. All other races
0.985
0.572
1.696
Asian vs. All other races
0.800
0.454
1.410
Age
3-5 vs. 0-2
3.396
2.622
4.398
6-8 vs. 0-2
4.673
3.611
6.045
9-11 vs. 0-2
3.881
2.985
5.047
12-14 vs. 0-2
2.629
2.008
3.443
15-17 vs. 0-2
1.545
1.156
2.065
3-5 vs. 6-8
0.727
0.596
0.887
3-5 vs. 9-11
0.875
0.712
1.075
3-5 vs. 12-14
1.292
1.042
1.601
3-5 vs. 15-17
2.198
1.729
2.795
6-8 vs 9-11
1.204
0.982
1.477
6-8 vs 12-14
1.777
1.436
2.199
6-8 vs 15-17
3.025
2.382
3.841
9-11 vs 12-14
1.476
1.186
1.837
9-11 vs 15-17
2.512
1.968
3.207
12-14 vs 15-17
1.702
1.324
2.189
Family $ 35 -74,999 vs. $ 0-34,999
1.042
0.868
1.249
$ 75 -99,999 vs. $ 0-34,999
1.363
1.084
1.715
Income $ 100,000 + vs. $ 0-34,999
1.524
1.270
1.830
$ 35 -74,999 vs. $ 75 -99,999
0.764
0.609
0.960
$ 35 -74,999 vs. $ 100,000 +
0.683
0.572
0.816
$ 75 -99,999 vs. $ 100,000 +
0.894
0.719
1.112
Note. Data Source: NHIS, 2015.
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The highest odds ratios were for children among the 6-8 age group who were
4.673 times more likely to receive the LAIV vaccine than children ages 0-2 and 3.025
times more likely to receive LAIV than children ages 15-17. Children ages 0-2, in which
LAIV is not recommended for, were less likely overall to receive LAIV than all other age
groups in the study. Children ages 9-11 were also more likely to receive the LAIV
vaccine than their peers as they fit into the ACIP age recommendation group.
White children were 1. 565 times more likely to receive the LAIV vaccine than
Asian children. In fact, White children were more likely to receive the LAIV vaccine than
Black (1.271) and Hispanic (1.523) children as well.
Children with a family income of $100,000 or more were 1.524 times more likely
to receive the LAIV vaccine than those with a family income of $0- 34,999 annually.
Children with a family income of $75 -99,999 were 1.363 times more likely to receive
the LAIV vaccine than those with a family income of $0- 34,999 annually.
For Research Question 1, we reject the null hypothesis in favor of the alternative
hypothesis for race, age, and family income and we fail to reject the null for health
insurance coverage. There is a relationship between age, race, family income and vaccine
type (LAIV/ IIV) among U.S. children for flu season 2014-2015. Those who received
LAIV were most likely to be White elementary school age children with a family income
of 75,000+ for the 2014-2015 flu season. Health insurance coverage was very high for
this population (96.3% for IIV, 98.1% for LAIV) indicating that the sample of uninsured
individuals may have been too low to address a relationship among variables. In addition,
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most of the LAIV cases were clustered around the ACIP recommended age of 2-8 years
of age considered the preferred flu vaccine type for the 2014-2015 flu season.
Data Analysis Research Question 2
Research Question 2: What was the relationship between age, race, family
income, health insurance status, and vaccine type (LAIV/ IIV) among U.S. children for
flu season 2015-2016?
H02: There is no relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2015-2016.
Ha2: There is a relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/IIV) among U.S. children for flu season 2015-2016.
Analysis of the 2015-2016 flu season. The same analysis approach as used in
Research Question 1 was also used for Research Question 2. Chi-square was used to
assess each independent variable by itself, and logistic regression was used to evaluate
these variables in a model. Tables 14- 17 show how the socioeconomic and demographic
variables are distributed among vaccine recipients their impact on vaccine type. As in
2014-2015, more patients received IIV compared to LAIV in the 2015-2016 flu season
(79.8% vs. 20.2%). Table 14 shows that the distributions of ages differed by vaccine
type. In the IIV group, the percentage within each age category ranged from a low of 13.7
% (9-11year old) to a high of 18.9 % (ages 0-2 years old) with an average age of 6-8.
Within the LAIV group the range of percentages within each age category range from a
low of 8.6 % (0-2 years of age) to a high of 23.4 % (6-8 years old) with an average age of
6-8.
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Table 14
2015-2016 Age and Vaccine Type Frequencies
Vaccine type
IIV
LAIV
0-2
712 (18.9%)
82 (8.6%)
3-5
703 (18.7%)
198 (20.7%)
6-8
544 (14.4%)
223 (23.4%)
9-11
517 (13.7%)
200 (20.9%)
12-14
639 (17.0%)
151 (15.8%)
15-17
651 (17.3%)
101 (10.6%)
Total
3766 (79.8%)
955 (20.2%)
Note. Data Source: NHIS, 2016.
Age

Total
794 (16.8%)
901 (19.1%)
767 (16.2%)
717 (15.2%)
790 (16.7%)
752 (15.9%)
4721 (100.0%)

Table 15 describes insurance coverage by vaccine type. Most participants had
some type of insurance coverage (97.8% for IIV, 99.4% for LAIV). More participants
receiving IIV had public insurance compared to those receiving LAIV (35.5% vs.
32.7.0%) and private insurance (58.5% for IIV, 60.7% for LAIV).
Table 15
2015-2016 Health Coverage and Vaccine Type Frequencies
Vaccine type
IIV
LAIV
Private
2203 (58.5%)
580 (60.7%)
Public
1337 (35.5%)
312 (32.7%)
Other coverage
121 (3.2%)
34 (3.6%)
Uninsured
105 (2.8%)
29 (3.0%)
Total
3766 (79.8%)
955 (20.2%)
Note. Data Source: NHIS, 2016.
Health Coverage

Total
2783 (58.9%)
1649 (34.9%)
155 (3.3%)
134 (2.8%)
4721 (100.0%)

Table 16 describes the distribution of race which differed between vaccine type.
Most vaccine recipients were either White (54.8% IIV, 60.4% LAIV) or Hispanic
(22.2%IIV, 19.9% LAIV).
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Table 16
2015-2016 Race and Vaccine Type Frequencies
Vaccine type
IIV
LAIV
Hispanic
836 (22.2%)
190 (19.9%)
White
2063 (54.8%)
577 (60.4%)
Black
459 (12.2%)
110 (11.5%)
Asian
302 (8.0%)
63 (6.6%)
All other race groups
106 (2.8%)
15 (1.6%)
Total
3766 (79.8%)
955 (20.2%)
Note. Data Source: NHIS, 2016.
Race

Total
1026 (21.7%)
2640 (55.9%)
569 (12.1%)
365 (7.7%)
121 (2.6%)
4721 (100.0%)

Table 17 describes family income. Family income was similar for both IIV and
LAIV recipients. Twenty-six % of children who received the flu vaccine were in the
lowest income group (IIV 26.4% and LAIV 24.3%) and 34.4 %were in the highest
income group (LAIV 35.9% and 34% for IIV).
Table 17
2015-2016 Family Income and Vaccine Type Frequencies
Vaccine type
IIV
LAIV
$0 -$34,999
996 (26.4%)
232 (24.3%)
$35,000 - $74,999
991 (26.3%)
256 (26.8%)
$75,000 - $99,999
498 (13.2%)
124 (13.0%)
$100,000 +
1281 (34.0%)
343 (35.9%)
Total
3766 (79.8%)
955 (20.2%)
Note. Data Source: NHIS, 2016.
Family Income

Total
1228 (26.0%)
1247 (26.4%)
622 (13.2%)
1624 (34.4%)
4721 (100.0%)

Logistic regression was used to describe the data and explain any relationship
between vaccine type and the independent variables (covariates). Logistic regression
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using vaccine type (probability modeled as LAIV) was applied to assess the relationship
amongst age group, insurance type, race, family income.
The reduced model was determined a better fit when health insurance status and
family income were determined not significant through initial analysis. The logistic
regression model was statistically significant, χ2(15) = 262.482, p = .000. The Wald test
of significance indicated that age (p = .000) and race (p= .000) were all statistically
significant in relation to LAIV uptake. Table 18 shows the results of the logistic
regression analysis used to address Research Question 2.
Table 18
Logistic Regression Reduced Model Flu Season 2015-2016

B

S.E.

Age
3-5
.894
.107
6-8
1.273 .108
9-11
1.221 .110
12-14
.729
.112
15-17
.295
.118
Race
White
.228
.073
Black
.058
.105
Asian
-.089
.125
Other race groups
-.462
.219
Constant
-.911
.053
Note. Data Source: NHIS, 2016.

Wald
220.61
69.557
139.332
124.323
42.687
6.197
23.707
9.595
.303
.499
4.442
297.960

df
5
1
1
1
1
1
4
1
1
1
1
1

Sig.
.000
.000
.000
.000
.000
.013
.000
.002
.582
.480
.035
.000

Exp(B)

95% CI for
Exp(B)
Lower Upper

2.445
3.571
3.391
2.073
1.343

1.982
2.891
2.736
1.666
1.065

3.017
4.412
4.203
2.579
1.694

1.256
1.059
.915
.630
.402

1.087
.863
.716
.410

1.450
1.301
1.170
.968

Two of the four covariates are significant (p < 0.05). Insurance coverage (p =
0.652) and family income (p = 0.920) were not statistically significant. Based on this a
reduced model eliminating insurance coverage from the model was run. The Hosmer-
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Lemeshow statistic from the reduced model was p = 0.4390 suggesting a slightly better
fit to the data. As a result, inferences are based on this reduced model.
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Table 19
2015-2016 Demographic characteristics and Vaccine Type Odds Ratios
Odds Ratio Estimates and Wald Confidence Intervals
Independent Variables
Race
White vs. Hispanic
Black vs. Hispanic
Asian vs. Hispanic
All other races vs. Hispanic
White vs. Black
White vs. Asian
White vs. All other races
Black vs. Asian
Black vs. All other races
Asian vs. All other races
Age
3-5 vs. 0-2
6-8 vs. 0-2
9-11 vs. 0-2
12-14 vs. 0-2
15-17 vs. 0-2
3-5 vs. 6-8
3-5 vs. 9-11
3-5 vs. 12-14
3-5 vs. 15-17
6-8 vs 9-11
6-8 vs 12-14
6-8 vs 15-17
9-11 vs 12-14
9-11 vs 15-17
12-14 vs 15-17
Note. Data Source: NHIS, 2016.

Odds Ratio
1.261
1.059
0.920
0.627
1.191
1.370
2.011
1.115
1.689
1.468
2.453
3.590
3.398
2.084
1.351
0.683
0.722
1.177
1.815
1.057
1.723
2.657
1.631
2.515
1.542

95% Confidence Limits
1.047
1.517
0.813
1.379
0.669
1.265
0.355
1.107
0.945
1.500
1.024
1.833
1.156
3.500
0.813
1.627
0.940
3.032
0.796
2.706
1.857
3.239
2.755
4.737
2.565
4.503
1.559
2.785
0.991
1.843
0.547
0.853
0.575
0.906
0.928
1.493
1.396
2.361
0.843
1.325
1.360
2.183
2.046
3.452
1.281
2.076
1.928
3.282
1.171
2.031
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The highest odds ratios were for children among the 6-8 age group who were
3.590 times more likely to receive the LAIV vaccine than children ages 0-2 and 65%
more likely to receive LAIV than children ages 15-17. Children ages 0-2 were less likely
overall to receive LAIV than all other age groups in the study. Children ages 9-11 and
12-14 were also more likely to receive the LAIV vaccine than their peers. White children
were 1.370 times more likely to receive the LAIV vaccine than Asian children. In fact,
White children were more likely to receive the LAIV vaccine than Black (1.191),
Hispanic (1.261), and all other race (2.011) children as well. For Research Question 2,
the reduced model including race and age provided the best fit. showing there these
variables and vaccine type (LAIV/ IIV) among U.S. children for flu season 2015-2016.
Those who received LAIV during the 2015-2016 flu season were also most likely to be
White elementary school age children.
Data Analysis Research Question 3
Research Question 3: What was the relationship between age, race, family
income, health insurance status, and vaccine type (LAIV/ IIV) among U.S. children for
flu season 2016-2017?
H03: There is no relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2016-2017.
Ha3: There is a relationship between age, race, family income, health insurance
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2016-2017.
Analysis of the 2016-2017 flu season. The same statistical approach was used as
was used for Research Question 1 and Research Question 2. Tables 20- 23 show how the
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socioeconomic-demographic variables are distributed among vaccine recipients their
impact on vaccine type. Overall, many more patients received IIV compared to LAIV in
the 2015-2016 flu season (92.5% vs. 7.5%). Table 20 shows that the distributions of ages
differed by vaccine type. In the IIV group, the percentage within each age category
ranged from a low of 14.8 % (9-11year old) to a high of 18.1 % (ages 3-5years old) with
an average age of 6-8. Within the LAIV group the range of percentages within each age
category range from a low of 11.3 % (15-17 years of age) to a high of 24.1% (6-8 years
old) with an average age of 6-8.
Table 20
2016-2017 Age and Vaccine Type Frequencies
Vaccine type
IIV
LAIV
0-2
555 (17.0%)
33 (12.4%)
3-5
591(18.1%)
37 (13.9%)
6-8
549 (16.8%)
64 (24.1%)
9-11
484 (14.8%)
61(22.9%)
12-14
546 (16.7%)
41(15.4%)
15-17
538 (16.5%)
30 (11.3%)
Total
3263 (92.5%)
266 (7.5%)
Note. Data Source: NHIS, 2017.
Age

Total
588 (16.7%)
628 (17.8%)
613 (17.4%)
545 (15.4%)
587 (16.6%)
568 (16.1%)
3529 (100.0%)

Table 21 describes insurance coverage by vaccine type. Most participants had
some type of insurance coverage (97.3% for IIV, 97.7% for LAIV). More participants
receiving LAIV had public insurance compared to those receiving the Flu shot (35.3% vs.
33.4%) while the opposite was true for those having private insurance (60.0% for IIV,
57.1% for LAIV).
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Table 21
2016-2017 Health Coverage and Vaccine Type Frequencies
Vaccine type
IIV
LAIV
Private
1958 (60.0%)
152 (57.1%)
Public
1089 (33.4%)
94 (35.3%)
Other coverage
127 (3.9%)
14 (5.3%)
Uninsured
89 (2.7%)
6 (2.3%)
Total
3263 (92.5%)
266 (7.5%)
Note. Data Source: NHIS, 2017.
Health Coverage

Total
2110 (59.8%)
1183 (33.5%)
141(4.0%)
95 (2.7%)
3529 (100.0%)

Table 22 describes the distribution of race which differed between vaccine type.
Most vaccine recipients were Hispanic (22.5%IIV, 22.2% LAIV) or White (56.7% IIV,
53.8% LAIV).
Table 22
2016-2017 Race and Vaccine Type Frequencies
Vaccine type
IIV
LAIV
Hispanic
734 (22.5%)
59 (22.2%)
White
1851(56.7%)
143 (53.8%)
Black
357 (10.9%)
40 (15.0%)
Asian
258 (7.9%)
16 (6.0%)
All other race groups
63 (1.9%)
8 (3.0%)
Total
3263 (92.5%)
266 (7.5%)
Note. Data Source: NHIS, 2017.
Race

Total
793 (22.5%)
1994 (56.5%)
397 (11.2%)
274 (7.8%)
71(2.0%)
3529 (100%)

Table 23 describes family income. More IIV recipients were in the highest
income group (38.4% vs. 37.6% for LAIV) while more recipients in the LAIV group
were in the lowest income group (24.6% vs. 27.1% for IIV).
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Table 23
2016-2017 Family Income and Vaccine Type Frequencies
Vaccine type
IIV
LAIV
$0 - $34,999
802 (24.6%)
72 (27.1%)
$35,000 - $74,999
831 (25.5%)
69 (25.9%)
$75,000 - $99,999
376 (11.5%)
25 (9.4%)
$100,000 and over
1254 (38.4%)
100 (37.6%)
Total
3263 (92.5%)
266 (7.5%)
Note. Data Source: NHIS, 2017.
Family Income

Total
874 (24.8%)
900 (25.5%)
401(11.4%)
1354 (38.4%)
3529 (100%)

Logistic regression was used to describe the data and explain any relationship
between vaccine type and the independent variables (covariates). Logistic regression
using vaccine type (probability modeled as LAIV) was applied to assess the relationship
amongst age group, insurance type, race, family income.
Before interpreting the model, the model containing covariates needs to be
checked that at least 1 covariate is different from 0 by testing that the global null
hypothesis=0. A p-value<0.0001 was obtained allowing for rejection of this null
hypothesis. This suggests that at least 1 covariate in the model is different from 0. In
addition, a goodness-of-fit statistic, the Hosmer-Lemeshow test, is applied to the resulting
model to check that the model is correctly specified, the data do not conflict with the
assumptions made by the model. The obtained p-value=0.818 suggests that we cannot
reject the hypothesis that the fitted model is correct.
The reduced model was determined a better fit when health insurance status was
determined not significant through initial analysis. Table 25 shows the results of the
logistic regression analysis used to address Research Question 3. The logistic regression
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model was statistically significant, χ2(15) = 34.831, p = .003. The Wald test of
significance indicated that age (p = .000) and race (p = .027) were statistically significant
in relation to LAIV uptake.
Table 24
Logistic Regression Reduced Model Flu Season 2016-2017

B

S.E.

Age
3-5
.041
.180
6-8
.670
.163
9-11
.734
.166
12-14
.220
.176
15-17
-.069
.189
Race
White
-.039
.119
Black
.299
.160
Asian
-.280
.213
Other race groups
.470
.300
Constant
-1.774
.077
Note. Data Source: NHIS, 2017.

Wald
48.972
.053
16.798
19.685
1.550
.134
10.942
.105
3.499
1.722
2.456
529.903

df
5
1
1
1
1
1
4
1
1
1
1
1

Sig. Exp(B)
.000
.819
1.042
.000
1.954
.000
2.084
.213
1.246
.714
.933
.027
.745
.962
.061
1.349
.189
.756
.117
1.599
.000
1.70

95% CI for
Exp(B)
Lower Upper
.733
1.418
1.507
.881
.645

1.482
2.691
2.883
1.760
1.351

.762
.986
.497
.889

1.214
1.846
1.148
2.878

Two of the four covariates are significant (p<0.05). Insurance coverage (p =
0.778) and Family Income (p = 0.761) were not statistically significant. Based on this a
reduced model eliminating insurance coverage from the model was run. The HosmerLemeshow statistic from the reduced model was p = 0.170 suggesting a better fit to the
data. As a result, inferences are based on this reduced model. Table 25 shows the odds
ratios and CIs for the 2016-2017 flu season.
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Table 25
2016-2017 Demographic Characteristics and Vaccine Type Odds Ratios
Odds Ratio Estimates and Wald Confidence Intervals
Independent Variables
White vs. Hispanic
Black vs. Hispanic
Asian vs. Hispanic
all other races vs. Hispanic
White vs. Black
White vs. Asian
White vs. all other races
Black vs. Asian
Black vs. all other races
Asian vs. all other races
3-5 vs. 0-2
6-8 vs. 0-2
9-11 vs. 0-2
12-14 vs. 0-2
15-17 vs. 0-2
3-5 vs. 6-8
3-5 vs. 9-11
3-5 vs. 12-14
3-5 vs. 15-17
6-8 vs 9-11
6-8 vs 12-14
6-8 vs 15-17
9-11 vs 12-14
9-11 vs 15-17
12-14 vs 15-17
Note. Data Source: NHIS, 2017.

Odds Ratio
1.777
1.216
1.155
1.227
1.461
1.538
1.448
1.053
0.991
0.941
3.386
4.667
3.920
2.676
1.570
0.726
0.864
1.265
2.157
1.191
1.744
2.973
1.465
2.497
1.705

95% Confidence Limits
1.516
2.082
0.966
1.531
0.878
1.520
0.727
2.072
1.185
1.800
1.190
1.989
0.865
2.423
0.775
1.431
0.577
1.703
0.537
1.650
2.616
4.384
3.609
6.035
3.017
5.094
2.045
3.502
1.175
2.097
0.595
0.885
0.704
1.060
1.022
1.567
1.698
2.740
0.971
1.459
1.410
2.157
2.343
3.772
1.178
1.822
1.958
3.185
1.326
2.191
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The highest odds ratios were for children among the 6-8 age group were 4.667
times more likely to receive the LAIV vaccine than children ages 0-2 and 3.920 times
more likely to receive LAIV than children ages 9-11. Children ages 3-5 were less likely
overall to receive LAIV than children 6-8 years of age. Children ages 0-2 were also more
likely to receive the LAIV vaccine than their peers. White children were 1.777 times
more likely to receive the LAIV vaccine than Hispanic children. In fact, White children
were more likely to receive the LAIV vaccine than Black (1.461) and Asian (1.538)
children. For Research Question 3, we reject the null hypothesis in favor of the
alternative hypothesis for race and age; we fail to reject the null for health insurance
coverage and family income. There is a relationship between age, race, and vaccine type
(LAIV/ IIV) among U.S. children for flu season 2015-2016. Those who received LAIV
during the 2016-2017 flu season were also most likely to be White elementary school age
children.
Data Analysis Research Question 4
Research Question 4: What was the relationship between influenza vaccine type
(LAIV/IIV) of U.S. children and ACIP recommendations indicated by flu seasons 20142015, 2015-2016, and 2016-2017?
H04: There is no relationship between influenza vaccine type (LAIV/IIV) of U.S.
children and ACIP recommendations indicated by flu seasons 2014-2015 (LAIV
preferred), 2015-2016 (LAIV & IIV) and 2016-2017 (IIV preferred).
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Ha4: There is a relationship between influenza vaccine type (LAIV/IIV) of U.S.
children and ACIP recommendations indicated by flu seasons 2014-2015, 2015-2016,
and 2016-2017.
Analysis of three consecutive flu seasons. Due to lack of efficacy, ACIP did not
recommend LAIV for the 2016-2017 flu season. A chi-square test of homogeneity was
used to evaluate the relationship between ACIP recommendations by flu season and
vaccine uptake (LAIV or IIV) to evaluate the impact of this change in recommendation.
Table 26 shows the results by vaccine type. These results showed that IIV was the
preferred vaccine for each year regardless of the ACIP recommendation. There was a
statistically significant difference between all three independent binomial proportions
χ2(2) = 423.238, p = 0.000 indicating that the proportion of patients receiving LAIV and
IIV are significantly different. Approximately 75 % of patients received IIV, in 20142015, and 2015-2016 and this increased to 92.5 % of patients receiving the vaccine in
2016-2017. This reduction of LAIV use in the 2016-2017 flu season is consistent with
ACIP recommendations.
Table 26
Flu Seasons and Vaccine Type Cross-Tabulation Post Hoc Test
Vaccine
Year
Type
2014-2015
2015-2016
IIV
3832a (75.2)
3766b (79.2)
LAIV
1265a (24.8)
955b (20.2)
Total
5097
4721
Note. Data Source: NHIS, 2015, 2016, 2017.

2016-2017
3263c (92.5)
266c (7.5)
3529

Total
10861 (81.4)
2486 (18.6)
13347
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The next step was to evaluate if, in addition to ACIP recommendations changing,
did any of the socioeconomic-demographic status variables also impacted or were they
impacted by the change in recommendation. This was achieved by looking at the
incidence of LAIV vaccination across the three flu seasons. Table 27 shows the age
distribution of for all three Flu seasons for LAIV recipients only. Overall the number of
children receiving LAIV in 2016-2017 was smaller than in earlier seasons indicating an
impact of the ACIP recommendations. LAIV coverage was consistent across all age
groups except the youngest (0-2) for all three years. Children ages 0-2 had a slight
increase in LAIV uptake (12.4 %) for the 2016-2017 flu season even though LAIV is not
recommended for their age group or the flu season. However, this must be interpreted
based on the smaller number of children receiving LAIV in the 2016-2017 season.
Table 27
Age Distribution of LAIV Recipients for All Flu Seasons
Year
2014-2015
2015-2016
0-2
93 (7.4%)
82 (8.6%)
3-5
274 (21.7%)
198 (20.7%)
6-8
313 (24.7%)
223(23.4%)
9-11
261 (20.6%)
200 (20.9%)
12-14
200 (15.8%)
151(15.8%)
15-17
124 (9.8%)
101(10.6%)
Total
1265
955
Note. Data Source: NHIS, 2015, 2016, 2017.
Age

2016-2017
33 (12.4%)
37 (13.9%)
64 (24.1%)
61(22.9%)
41(15.4%)
30 (11.3%)
266

Total
208 (8.4%)
509 (20.5%)
600 (24.1%)
522 (21.0%)
392(15.8%)
255(10.3%)
2486

To further evaluate how socioeconomic status and demographic characteristics
may influence the differences in LAIV vaccine uptake by year a chi-square test of
homogeneity was conducted between flu season (2014-2015, 2015-2016, and 2016-2017)
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by socioeconomic-demographic status (race, family income, and health insurance status)
for LAIV recipients to determine if variations in socioeconomic-demographic status
could account for the differences in LAIV uptake between Flu seasons 2014-2015, 20152016 and 2016-2017. Table 28 shows the health insurance distribution of for all three Flu
seasons for LAIV recipients only. Health insurance coverage among LAIV recipients
remained consistent across all three flu seasons. No relationship between year and health
coverage was observed (p = 0.087).
Table 28
Health Coverage of LAIV Recipients for All Flu Seasons
Year
2014-2015
2015-2016
Private
782 (61.8%)
580 (60.7%)
Medicaid/ Public
429 (33.9%)
312 (32.7%)
Other Coverage
30 (2.4%)
34 (3.6%)
Uninsured
24 (1.9%)
29 (3.0%)
Total
1265
955
Note. Data Source: NHIS, 2015, 2016, 2017.
Health Coverage

2016-2017
152 (57.1%)
94 (35.3%)
14 (5.3%)
6 (2.3%)
266

Total
1514 (60.9%)
835 (33.6%)
78 (3.1%)
59 (2.4%)
2486

Table 29 shows the race distribution of for all three Flu seasons for LAIV
recipients only. Race was consistent across all three flu seasons. No relationship between
year and race was observed (p = 0.303).
Table 29
Race Distribution of LAIV Recipients for All Flu Seasons

Race
Hispanic
White

2014-2015
286 (22.6%)
727 (57.5%)

Year
2015-2016
190 (19.9%)
577 (60.4%)

2016-2017
59 (22.2%)
143 (53.8%)

Total
535 (21.5%)
1447 (58.3%)
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Black
144 (11.4%)
110 (11.5%)
Asian
88 (7.0%)
63 (6.6%)
All other race
20 (1.6%)
15 (1.6%)
groups
Total
1265
955
Note. Data Source: NHIS, 2015, 2016, 2017.

40 (15.0%)
16 (6.0%)
8 (3.0%)

294 (11.8%)
167 (6.7%)
43 (1.7%)

266

2486

Table 30 shows the family income distribution of for all three Flu seasons for
LAIV recipients only. Family income was also consistent across all three flu seasons,
with a minimal decline in the percent of LAIV recipients in the $75,000 to $99,999
family income group from the 2014-2015 flu season (12.9%) to the 2016-2017 flu season
(9.4%). No relationship between year and Family income was observed (p = 0.572).
Table 30
Family Income of LAIV Recipients for All Flu Seasons
Year
2014-2015
2015-2016
$0 - $34,999
331 (26.2%)
232 (24.3%)
$35,000 -$74,999
309 (24.4%)
256 (26.8%)
$75,000 -$99,999
163 (12.9%)
124 (13.0%)
$100,000 and over
462 (36.5%)
343 (35.9%)
Total
1265
955
Note. Data Source: NHIS, 2015, 2016, 2017.
Family Income

2016-2017
72 (27.1%)
69 (25.9%)
25 (9.4%)
100 37.6%)
266

Total
635 (25.5%)
634 (25.5%)
312 (12.6%)
905 (36.4%)
2486

All three flu seasons resulted in significantly different flu vaccine uptake by type
consistent with ACIP recommendations. Socioeconomic status and demographic
characteristics were not considered influential in LAIV uptake for race, health insurance
status, or family income when comparing all three flu seasons. ACIP recommendations
by age and year appeared to have the greatest impact on flu vaccine choice for this
sample population.
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Summary
The purpose of this study is to examine the relationship between seasonal
influenza vaccination ACIP recommendations, socioeconomic status, demographic
characteristics, and vaccine uptake among children over three consecutive flu seasons.
The dependent variable is influenza vaccine type (LAIV and IIV) among U.S. children.
The independent variables are ACIP influenza vaccine recommendation by flu season
including flu seasons 2014-2015, 2015-2016, and 2016-2017 and socioeconomicdemographic status indicated by age, race, family income, and health insurance status.
For research questions 1-3 forward, binomial logistic regression was performed to
ascertain the effects of age, race, health insurance status, and family income on vaccine
uptake by type LAIV or IIV. For research question 4 a chi-square test of homogeneity
was used to evaluate the relationship between ACIP recommendations by flu season and
vaccine uptake (LAIV or IIV) for all three flu seasons. These results showed that IIV was
the preferred vaccine for each year regardless of the ACIP recommendation. To further
evaluate how socioeconomic status and demographic characteristics may influence the
differences in LAIV vaccine uptake by year a chi-square test of homogeneity was
conducted between flu season (2014-2015, 2015-2016, and 2016-2017) by
socioeconomic-demographic status (race, family income, and health insurance status) for
LAIV recipients.
For the 2014-2015 flu season, a relationship between age, race, family income,
and vaccine type (LAIV/ IIV) was established among U.S. children included in this
study. Those who received LAIV were most likely to be White elementary school age
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children with a family income of 75,000+ for the 2014-2015 flu season. The 2015-2016
and 2016-2017 flu seasons showed a relationship between demographic characteristics
(age and race) and vaccine type (LAIV/ IIV) was established among U.S. children
included in this study. Those who received LAIV during the 2015-2016 and 2016-2017
flu season were also most likely to be White elementary school age children. All three flu
seasons resulted is significantly different flu vaccine uptake by type consistent with ACIP
recommendations. Socioeconomic status and demographic characteristics were not
considered influential in LAIV uptake for race, health insurance status, or family income.
ACIP recommendations by age and year appeared to have the greatest impact on flu
vaccine choice for this sample population.
Section 4 will present a summary of key findings, analyzes, interpretation,
limitations to generalizability, validity, reliability, recommendations for further research,
and implications for positive social change.
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Section 4: Application to Professional Practice and Implications for Social Change
Introduction
I examined the relationship between seasonal influenza vaccination ACIP
recommendations, socioeconomic status, demographic characteristics, and vaccine uptake
among children over three consecutive flu seasons. LAIV was the recommended choice
for children 2-8 during the 2014-2015 flu season, both LAIV and IIV were equally
recommended for the 2015-2016 flu season, and the LAIV recommendation was
discontinued for the 2016-2017 season due to studies showing limited efficacy against
A/H1N1 (Flannery & Chung, 2016). In addition, multiple socioeconomic factors and
demographic characteristics have the potential to influence vaccine choice. The
dependent variable was influenza vaccine type (LAIV and IIV) among U.S. children. The
independent variables were ACIP influenza vaccine recommendation by flu season
(2014-2015, 2015-2016, and 2016-2017), and socioeconomic-demographic status
indicated by age, race, family income, and health insurance status. Secondary
surveillance data were taken from the CDC to evaluate vaccine uptake by type among
children over three recent flu seasons with different children sampled each year.
For the 2014-2015 flu season, a relationship between age, race, family income,
and vaccine type (LAIV/ IIV) was established among U.S. children included in this
study. Those who received LAIV were most likely to be White elementary school age
children with a family income of 75,000+ for all the flu seasons included in this study.
The 2015-2016 and 2016-2017 flu seasons showed a relationship between demographic
characteristics (age and race) and vaccine type (LAIV/ IIV). However, socioeconomic-
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demographic status was not considered influential in LAIV uptake for race, health
insurance status, or family income. Based on the results, ACIP recommendations by age
and year had the greatest impact on flu vaccine choice for this sample population.
Interpretation of the Findings
The findings of this study extend the current knowledge about flu vaccine uptake
in the community by addressing issues associated with flu vaccine choice. Most flu
vaccine research has evaluated the efficacy of the vaccine based on a test-negative design
(a variation of the case-control design). Few studies have evaluated influenza vaccine
uptake by type, socioeconomic status, demographic characteristics, and ACIP
recommendations. Thus, this study adds to current knowledge regarding influenza
vaccine uptake among children by identifying socioeconomic factors and demographic
characteristics that influence LAIV uptake in the community in addition to the impact of
ACIP recommendations on vaccine choice.
Perceptions of safety and efficacy are determining factors regarding seasonal flu
vaccination uptake (Galarce et al., 2011). For roughly 50% of flu vaccinated children,
parents reported no preference for either IIV or LAIV for both the 2014-2015 and 20152016 flu seasons (Santibanez, Kahn, & Bridges, 2018) The percentage who preferred
LAIV for 2014-2015 was 22.7%, and for 2015-2016 it was 21.7%, with 70% of those
preferring this method citing children’s fear of needles (Santibanez et al., 2018). Further,
the percentage of parents with a preference for IIV for 2014-2015 was 22.1%, and for
2015-2016 it was 24.7% (Santibanez et al., 2018).
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The current study showed that most children who received the LAIV were within
the age range recommended by the ACIP of 2-8 across all three flu seasons. In addition,
children 6-8 years of age consistently received the LAIV vaccine across all three seasons
with an average of 24.1% coverage, though the ACIP recommended no one receive the
LAIV vaccine for the 2016-2017 flu season. The American Academy of Pediatrics
recommended preference for the IIV vaccine for the 2018-2019 flu season but encourages
parents to vaccinate their children for the flu regardless of vaccine type, because
receiving the nasal vaccine is better than no vaccine (Munoz, 2018).
Additional findings from this study are that race was indicated as a determining
factor for choice between IIV and LAIV for each individual flu season. White children,
who were vaccinated for the flu, were more likely to receive LAIV than other races
included in this study. This is consistent with a recent study that showed White adult
Americans are more likely to receive the flu vaccine than other racial groups, especially
those with higher income (Abbas, Kang, Chen, Werre, & Marathe, 2018). This has
implications for improving vaccine uptake among adults by,
increasing awareness of the safety, efficacy and need for influenza vaccination,
leveraging the practices and principles of commercial and social marketing to
improve vaccine trust, confidence and acceptance, and lowering out-of-pocket
expenses and covering influenza vaccination costs through health insurance.
(Abbas et al., 2018, p.2).
These suggestions are consistent with the results of this study as well.
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Limitations of the Study
Cross-sectional quantitative research is used to investigate the relationship
between variables in their natural environment rather than a laboratory setting (Polit &
Hungler, 1999). This type of investigation often involves data from descriptive studies to
formulate hypotheses, determine a relationship between variables, and test theories.
Cross-sectional studies are used to evaluate the nature of relationships that exist and not
infer causality like traditional experimental studies (Creswell, 2012).
The data from the NHIS survey are cross-sectional, based on an annual sample
representing a changing cohort of subjects. In this case, the NHIS does not collect
information from all subgroup populations, omitting institutionalized individuals
including military families. One limitation is that this data are secondary, so the health
information collected does not include verifiable medical data or laboratory data (see
Rolnick et al., 2013). Some survey respondents may not be forthcoming about a behavior
many consider to be undesirable. Therefore, another limitation to this study is the use of
self-reported data, which involves setbacks such as reembrace error, reporting bias,
incorrect documentation, and loss of cases.
The greatest limit in this study involved measuring a relationship among
variables, which is the assumption of generalizability. Although statistical analysis of
data sets may reveal that two variables vary together, it does not mean they do. If the data
are not representative of the real population, study results could indicate a relationship
among variables that does not exist in the actual population. There are several unknown
factors called confounders that can be unaccounted for resulting in a false perception of a
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relationship among variables (Oleckno, 2002). In this study, potential confounders were
evaluated to try and control for these factors. However, other unknown factors could have
contributed to confounding not addressed in this study.
Recommendations
Further research is needed to evaluate the relationship among socioeconomic
status, demographic characteristics, ACIP recommendations, and Flu vaccine uptake in
the Community. While it is important to provide efficacy information to all parties
involved in providing flu vaccines to the community, it is also important to determine
what factors contribute to uptake especially among children who are most likely to be
infected with flu and transmit it to someone else. According to the CDC’s FluView
Influenza-Associated, pediatric mortality is highest between five and eleven years of age,
especially when combined with a secondary bacterial infection (CDC, 2016). School-age
children have the highest influenza transmission and infection rate, ranging from a 10-40
% attack rate yearly (Wilson et al., 2013). Over half of all flu vaccines in the U.S. are
administered to individuals ages 6 months to 17 years old (Peng-jun Lu et al., 2013).
According to the Morbidity and Mortality Weekly Report, the United States vaccination
coverage is consistently below the Healthy People 2020 goal of 70 % (Peng-jun Lu et al.,
2013).
In addition to the reported inconsistencies in flu vaccine efficacy, annual
influenza immunization recommendations have varied in children 2-8 years of age.
Inconsistencies in vaccine recommendations can negatively impact vaccine uptake in the
community by diminishing the patients perceived benefits of following vaccine
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recommendations (Mueller, Hill, Fontanesi, & Kopald, 2007). Studies show parents who
delayed and refused vaccine doses were more likely to have vaccine safety concerns and
perceive fewer benefits associated with these vaccines (Blyth et al., 2014; Cheney &
John, 2013; Smith et al., 2011).
Implications for Professional Practice and Social Change
The discontinued recommendation of LAIV for children in the U.S. has the
potential to affect influenza vaccine uptake and community outcomes due to the theory of
herd immunity and the transmission rate of illness from child to caregiver. LAIV was
developed to address issues associated with production and dissemination of IIV for
potential influenza pandemics (Penttinen & Friede, 2016). Production of IIV is timely
and administering the vaccine requires basic safety and infection control measures due to
its injectable nature. The LAIV option was initially determined to be ideal for mass
vaccination of children especially in a pandemic situation due to its superior efficacy,
ease of administration, greater production yield, rapid availability for unanticipated
serotypes, and user-friendly application (Penttinen & Friede, 2016). Discontinuation of
LAIV recommendations has the potential to greatly impact the community by reducing
the number of children effectively vaccinated against the flu resulting in an increase of
influenza exposure in the community.
Policies can directly influence the other levels by altering and influencing the
access and desire of flu vaccinations by making them unavailable, altering access,
reducing their perceived effectiveness, limiting affordability, or indicating belief of risk
associated with their use. The discontinued ACIP recommendation of the LAIV has the
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potential to negatively influence influenza vaccine uptake in general if the underlying
cause of LAIV’s reduced efficacy is not defined and addressed due to conflicting policy,
and inconsistent recommendations by governing bodies, local health departments, and
family practitioners. Improving vaccine recommendations and policy may lead to
increased vaccine uptake and result in fewer sick days, reduced suffering, increased
productivity, lower health cost and reduced illness and death associated with the flu virus
especially for those most at risk.
The potential contribution of this study is to add to current knowledge regarding
influenza recommendations and influenza vaccine uptake among children. This study
found that age and ACIP recommendations influence flu vaccine uptake in the
community. Additionally, it was concluded that family income and race might also play a
significant part in flu vaccine choice by type. Most flu vaccine research evaluates the
efficacy of the vaccine based on a test-negative design. Few studies evaluate influenza
vaccine uptake and ACIP recommendations. This study aimed to assess how ACIP
recommendations influence influenza vaccination rates among children in the United
States over the three most recent flu seasons.
Vaccination uptake is significantly influenced by social and psychological factors,
some of which are under-reported and poorly understood (Wheelock, Miraldo, Parand,
Vincent, & Sevdalis, 2014). Although structural barriers are known to limit vaccination
rates, social and psychological factors can also affect the decision to vaccinate children.
Perceptions about flu susceptibility and vaccine effectiveness significantly influence
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vaccination adoption (Wheelock et al., 2014). Evaluating current procedures and policies
could improve patient perceptions and access.
High vaccination coverage reduces exposure of unvaccinated persons to infection,
resulting in indirect protection in addition to direct protection for the those vaccinated
(Glezen, Gaglani, Kozinetz, & Piedra, 2010). The direct effect of immunity reduces
infection rates among vaccinated individuals resulting in less infection circulating in the
community, less influenza exposure, resulting in herd immunity by indirect means (Fine
et al., 2011). Increasing the number of school-age children immunized against the flu also
increases herd immunity by the indirect protection of household and community
members (Lind et al., 2014).
Conclusion
Seasonal influenza outbreaks are associated with considerable morbidity and
mortality in the United States (Hull & Ambrose, 2011; Weycker et al., 2005; Wilson et
al., 2013). Annual fall influenza vaccinations are the most effective method for
preventing influenza and its complications (Weycker et al., 2005). According to the
CDC’s FluView Influenza-Associated, Pediatric Mortality is highest between five and
eleven years of age, especially when combined with a secondary bacterial infection
(CDC, 2016). Yet annual influenza attack rates among school-age children, who play a
fundamental role in transmitting the infection to others, are as high as 42 % (Carpenter et
al., 2007).
The vaccination of children has been shown to reduce the impact of influenza on
the communities where they reside, which is of particular importance for at-risk
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populations such as those 65 years of age and older (Wilson, Sanchez, Blackwell,
Weinstein, & El Amin, 2013). Seasonal influenza is estimated to impact 10-20 % of the
United States population annually (Hull & Ambrose, 2011). The flu is rapidly transmitted
in large populations with close contact, especially in the fall and winter months during
the traditional academic school year. School-age children have the highest influenza
transmission and infection rate, ranging from a 10 to 40 % attack rate yearly (Wilson et
al., 2013). The World Health Organization recommends a seasonal flu vaccination
consisting of a 75 % coverage rate for high-risk populations (Longini & Halloran, 2005).
In addition to the reported inconsistencies in Flu vaccine efficacy, annual
influenza immunizations recommendations have varied dramatically in children 2-8 years
of age. Inconsistencies in vaccine recommendations can negatively impact vaccine
uptake in the community by diminishing the patients perceived benefits of following
vaccine recommendations (Mueller et al., 2007). Studies show parents who delayed and
refused vaccine doses were more likely to have vaccine safety concerns and perceive
fewer benefits associated with these vaccines (Blyth et al., 2014; Cheney & John, 2013;
Smith et al., 2011).
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